REVIEW

Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers

Aura D Herrera-Martínez^{1,2}, Leo J Hofland¹, María A Gálvez Moreno², Justo P Castaño², Wouter W de Herder¹ and Richard A Feelders¹

¹Division of Endocrinology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

²Maimonides Institute for Biomedical Research of Cordoba (IMIBIC); Reina Sofia University Hospital, Córdoba, Spain

Correspondence should be addressed to R A Feelders: r.feelders@erasmusmc.nl

Abstract

Some biomarkers for functioning and non-functioning neuroendocrine neoplasms (NENs) are currently available. Despite their application in clinical practice, results should be interpreted cautiously. Considering the variable sensitivity and specificity of these parameters, there is an unmet need for novel biomarkers to improve diagnosis and predict patient outcome. Nowadays, several new biomarkers are being evaluated and may become future tools for the management of NENs. These biomarkers include (1) peptides and growth factors; (2) DNA and RNA markers based on genomics analysis, for example, the so-called NET test, which has been developed for analyzing gene transcripts in circulating blood; (3) circulating tumor/endothelial/progenitor cells or cell-free tumor DNA, which represent minimally invasive methods that would provide additional information for monitoring treatment response and (4) improved imaging techniques with novel radiolabeled somatostatin analogs or peptides. Below we summarize some future directions in the development of novel diagnostic and predictive/prognostic biomarkers in NENs. This review is focused on circulating and selected tissue markers.

Key Words

- ▶ neuroendocrine neoplasms
- ▶ novel
- ▶ markers
- ▶ diagnosis
- ▶ prognosis

Endocrine-Related Cancer
(2019) **26**, R157–R179

Introduction

Neuroendocrine neoplasms (NENs) represent a heterogeneous group of rare neoplasms, which originate from enterochromaffin cells that are located throughout the whole body. NENs located in the gastrointestinal tract and pancreas are also referred to as gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) (Modlin *et al.* 2008, Xavier *et al.* 2016). The annual NENs incidence increases over time, although it is not known whether this is a true increase in NEN incidence, the result of increased use of (improved) diagnostic procedures or a combination of both (Xavier *et al.* 2016, Dasari *et al.* 2017).

NENs can be divided into ‘functional’ and ‘nonfunctional’ tumors. Functional NENs are able to produce, store and secrete bioactive peptides and can present with specific clinical syndromes related to the biological effects of these substances. Nonfunctional NENs can present with mechanical effects, that is, bowel obstruction or ischemia, but are also frequently discovered by the incidence during diagnostic procedures (Hofland *et al.* 2018). The clinical course of NENs can be highly variable and includes a spectrum ranging from well-differentiated, indolent growing tumors to

aggressive, highly proliferative tumors. Around 60–80% of NENS are metastasized when diagnosed (Modlin *et al.* 2010a). The overall 5-year survival rate of patients with NENs ranges between 35 and 82% in well- to moderately differentiated NENs and between 4 and 38% in poorly differentiated NENs (Pape *et al.* 2004, Yao *et al.* 2008). Survival is specifically determined by several parameters including the localization of the primary tumor (overall 5-year survival: 75.0% for jejunoileal, 42.9% for pancreatic NENs), tumor size, presence of vascular invasion, necrosis, surgical resection margin, metastasis, grade and stage of disease (particularly in G1/G2 NENs with localized, regional and distant disease survival rates of 223, 111 and 33 months have been reported respectively; (Pape *et al.* 2004, Veenendaal *et al.* 2006, Gao *et al.* 2018)). Since several factors are involved in NENs patients' survival, the use of nomograms that combine clinical, biochemical, histological and therapeutic characteristics has been proposed (Modlin *et al.* 2010b, Clift *et al.* 2017). These nomograms are mostly not validated yet and currently not used in clinical practice. Appropriate standardized diagnostic procedures are required to assure early diagnosis, monitor disease progression and guide an optimal treatment (Obergh *et al.* 2015). An ideal biomarker should have a high sensitivity for the diagnosis of NENs, to predict tumor clinical behavior and for the response to treatment (Turner *et al.* 2006). To date, only few diagnostic and therapeutic (reflecting treatment response) markers are available with limited performance, but new biomarkers are in development, including peptides/growth factors, DNA/RNA markers and circulating tumor cells. In this review, we describe the currently available and potential future diagnostic, prognostic and therapeutic biomarkers in NEN, with a focus on circulating factors.

Search strategy

We searched the Cochrane Library, MEDLINE and EMBASE up to March 2017. Publications from the past 5 years were predominantly selected. The reference lists of articles identified by this search strategy were screened for relevant publications. Commonly cited and important older publications were also included. Some review articles, but especially original articles, were included.

The following search terms, alone or in combination, were used: 'biomarkers', 'novel markers', 'neuroendocrine tumors', 'NETs', 'neuroendocrine neoplasms', 'NENs', 'circulating markers', 'tissue markers', 'therapeutic markers', 'diagnosis', 'chromogranin A', 'neuron-specific enolase', 'N-terminal pro-brain natriuretic peptide',

'5-hydroxyindoleacetic acid', 'pancreatic peptide', 'peptides and growth factors', 'DNA markers', 'epigenetic', 'genomic', 'mutations', 'germline', 'somatic', 'alternative lengthening of telomeres', 'whole-genome sequencing', 'chromatin remodeling', 'DNA repair', 'cell-free DNA', 'RNA markers', 'microRNAs', 'somatostatin receptor expression', 'O-6-methylguanine-DNA methyltransferase', 'mTOR pathway inhibitors', 'everolimus', 'temozolamide', 'alkylant-based chemotherapy', 'somatostatin analogs', 'sunitinib', 'immunotherapy', 'molecular biomarkers', 'epidermal growth factor receptor', 'vascular endothelial growth factor', 'Interleukin-8', 'stromal cell-derived factor-1 α ', 'circulating tumor cells', 'endothelial cells', 'white cells', 'placental growth factor', 'tuberous sclerosis complex', 'programmed death-1', 'programmed death-1 ligand'.

Currently available biomarkers for NENs

Currently used biochemical markers in NENs are usually hormones or amines secreted by NEN cells, which can be influenced by several factors including co-existent disease(s) and drugs, as shown in Table 1. These biomarkers add to diagnosis, but are insufficient to accurately diagnose NENs, to identify the primary tumor site or to differentiate tumor grading, especially due to sensitivity and specificity issues (Obergh *et al.* 2015). Despite this, some of them are considered for the diagnosis and follow-up of NENs according to several clinical guidelines as shown in Table 2. In Table 3, a summary of the sensitivity and specificity of currently used biomarkers in NENs is depicted.

Chromogranin A

Chromogranin A (CgA) is a protein expressed in the secretory granules of normal and neoplastic neuroendocrine cell types. It is released with peptide hormones and biogenic amines and is also the precursor for functional neuroendocrine peptides (Eskeland *et al.* 1996, D'Amico *et al.* 2014). Several guidelines recommend plasma CgA measurement during diagnosis, treatment and follow-up in GEP-NENs (Table 2). Baseline and serial CgA may predict clinical outcome, prognosis and tumor response (Arnold *et al.* 2008) and may be indicative for local progression in patients with liver involvement (Bajetta *et al.* 1999). Additionally, progressive decrease in CgA levels may be observed in patients with extensive metastatic spread and loss of neuroendocrine differentiation (Zatelli *et al.* 2007).

Table 1 Foods, drugs and other conditions which interfere with the results of current NENs biomarkers (Schwartz 1983, Batterham *et al.* 2003, Jin *et al.* 2015, Gut *et al.* 2016).

Current marker	False-positive results	False-negative results
5-HIAA	<i>Foods and drinks:</i> Fruits (banana, kiwis, avocado, pineapple, plums, tomato, aubergine, figs, grapefruit, melon), red wine, coffee, tea, chocolate, cheese, vegetables (black olives, spinach, broccoli, cauliflower) <i>Drugs:</i> Somatostatin analogs, levodopa, methyl dopa, heparin, isoniazid, monoamine oxidase inhibitors, methenamine, tricyclic antidepressants, phenothiazines, acetylsalicylic acid	<i>Drugs:</i> Paracetamol, naproxen, phenacetin, fluorouracil, testosterone, methysergide, acetanilide, reserpine, atenolol, pindolol, oxprenolol, ephedrine, diazepam, methocarbamol
Cg-A	<i>Foods and drinks:</i> 30–90 min after a meal <i>Drugs:</i> Proton pump inhibitors, histamine type-2 receptor antagonists <i>Diseases:</i> Atrophic gastritis, pancreatitis, chronic hepatitis, liver cirrhosis, impaired kidney function, chronic heart failure, acute coronary syndrome, untreated hypertension, rheumatoid arthritis, irritable bowel syndrome and inflammatory bowel disease <i>Others:</i> Strenuous exercise before the test	<i>Diseases:</i> Low proliferative, rapidly Proliferating and poorly differentiated NENs
Pancreatic polypeptide	<i>Foods and drinks:</i> 30–90 min after a meal <i>Diseases:</i> Uncontrolled diabetes mellitus <i>Others:</i> Increased age, exercise	<i>Drugs:</i> Atropine <i>Diseases:</i> Chronic pancreatitis, pancreatic resection

However, CgA is elevated in only 60–80% of patients with NENs and has a limited sensitivity of 60–83% and a relatively low specificity, that is, 72–85% (Table 3; Schurmann *et al.* 1992, Bajetta *et al.* 1999, Seregini *et al.* 2001, Stivanello *et al.* 2001, Nehar *et al.* 2004, Walter *et al.* 2012, Duque *et al.* 2013, Wang *et al.* 2014, Oberg *et al.* 2017). Moreover, proton pump inhibitors, atrophic gastritis and impaired kidney function can induce a rise in CgA levels (Ardill & O'Dorisio 2010, Oberg *et al.* 2017). The combination of CgA with other diagnostic methods, for example, somatostatin receptor scintigraphy, may increase its sensitivity (93%) and specificity (81%) (Kalkner *et al.* 1995, Cimitan *et al.* 2003, Namwongprom *et al.* 2008). Importantly, the sensitivity of CgA depends further on the threshold cut-off (Zatelli *et al.* 2007, Nolting *et al.* 2012, Oberg *et al.* 2017), NEN primary location (Baudin *et al.* 2001, Tomassetti *et al.* 2001, Nolting *et al.* 2012), endocrine-associated syndrome (Modlin *et al.* 2010a), disease spread, liver metastases (Zatelli *et al.* 2007, Nikou *et al.* 2008, Nolting *et al.* 2012, Walter *et al.* 2012) and the used assay (Ferrari *et al.* 2004). Despite its use being described in some clinical guidelines, some recent publications suggest a limited applicability as follow-up marker (Marotta *et al.* 2018). Importantly, different analytical properties of the CgA kits give different performances, a fact that must be taken into consideration when comparing results from different clinical studies.

Neuron-specific enolase

Neuron-specific enolase (NSE) is a soluble cerebral protein, which provides information on neural, neuroendocrine

and paraneuronal cells (Jorgensen *et al.* 1996). An increase in NSE levels is thought to be related to a high death rate of cells with neuroendocrine differentiation (Bajetta *et al.* 1999). NSE is probably the most reliable tumor marker in diagnosis, prognosis and follow-up of small-cell lung cancer (SCLC) (Isgro *et al.* 2015). This marker may be elevated in 38–40% of GEP-NENs patients, in particular, in those with high-grade tumors (Baudin *et al.* 1998, van Adrichem *et al.* 2016b). The specificity of NSE is similar to CgA but with lower sensitivity (Table 3; Grouzmann *et al.* 1990, Nobels *et al.* 1997, Baudin *et al.* 1998). NSE levels have been directly associated with tumor differentiation, aggressiveness and size (Baudin *et al.* 1998, van Adrichem *et al.* 2016b). Despite its limited sensitivity, NSE is inversely correlated to overall survival (OS) in ENETS TNM stage IV (van Adrichem *et al.* 2016b) and with shorter progression-free survival (PFS), even if CgA levels are normal (Yao *et al.* 2011).

N-terminal pro-brain natriuretic peptide

N-terminal pro-brain natriuretic peptide (NT-proBNP) is a peptide produced by myocardial cells in response to electrolyte and fluid balance. Despite it not being a specific NEN marker, its serum concentration is usually elevated in midgut-NENs with a sensitivity of 87% and a specificity of 80% (Oberg *et al.* 2015, Modlin *et al.* 2016). NT-proBNP is in particular used for evaluating carcinoid heart disease (CHD), and it has been reported that a cut-off value of 260 pg/mL has a sensitivity of 92% and specificity of 91% (Bhattacharyya *et al.* 2008). Interestingly, it has been

Table 2 Indications of current biomarkers in GEP-NENs according NCCN 2.2015, NANETS 2010, ESMO 2012, ENETS 2009–2016 and UKINETS 2012 guidelines.

Guideline	CgA	NSE	u-5HIAA	Others
NCCN (Kulke <i>et al.</i> 2015)	In immunohistochemistry to establish neuroendocrine differentiation For diagnosis (GEP-NENs) For follow-up (GEP-NENs)		For diagnosis (GEP-NENs) For follow-up (GEP-NENs)	PP: For PNEN diagnosis
NANETS 2010 (Boudreaux <i>et al.</i> 2010, Kulke <i>et al.</i> 2010)	For diagnosis (GEP-NENs, bronchial NENs**) For follow-up (GEP-NENs)	Diagnosis bronchial NENs Useful for follow-up (gut-NENs)**	For diagnosis (GEP-NENs) For follow-up (GEP-NENs)	
ESMO 2012 (Oberg <i>et al.</i> 2012)	For diagnosis (GEP- bronchial -NENs) For follow-up (GEP-bronchial-NENs)	For bronchial NENs Value as general marker	For midgut, bronchial NENs	PP: For non-functioning PNEN diagnosis
ENETS 2009–2016 (O'Toole <i>et al.</i> 2009, Niederle <i>et al.</i> 2016)	For diagnosis (GEP- bronchial -NENs) For follow-up (GEP-bronchial NENs) Useful in NEC	NEC diagnosis and follow-up	For midgut, bronchial NENs	
UKI NETS 2012 (Ramage <i>et al.</i> 2012)	For diagnosis For follow-up		In bronchopulmonary and gut-NENs For follow-up carcinoid syndrome	NT-proBNP: To rule out CHD morbidity, midgut NENs PP: alternative when CgA is within the reference range NKA: in gut-NENs

**Suggested. **Limited use.

CHD, carcinoid heart disease; ENETS, European Neuroendocrine Tumor Society; ESMO, European Society of Medical Oncology; Gut-NENs include tumors in the jejunum, ileum, appendix, and cecum; NANETS, North American Neuroendocrine Tumor; NCCN, National Comprehensive Cancer Network; NEC, neuroendocrine carcinoma; NKA, neurokinin A; NSE, plasmatric neuron-specific enolase; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; PNEN, pancreatic neuroendocrine neoplasm; PP, pancreatic polypeptide; u-5HIAA, urinary 5-Hydroxy-indolacetic acid; UKI NETS, UK and Ireland Neuroendocrine Tumour Society.

suggested that patients with elevated NT-proBNP levels combined with increased CgA levels have a worse OS when compared to CgA alone (Korse *et al.* 2009b, Oberg *et al.* 2015). Importantly, NT-proBNP is not disease specific; thus, further studies for evaluating its applicability in the progression of CHD are still required (Bhattacharyya *et al.* 2008).

5-hydroxyindoleacetic acid

Serotonin, produced by (midgut) NENs, is the most prominent hormone associated with diarrhea and flushes in carcinoid syndrome. Its metabolite, 5-hydroxyindoleacetic acid (5HIAA), measured in 24-h urine is used as a diagnostic and follow-up marker (Korse *et al.* 2009a). Urinary (u) 5HIAA levels are not directly related to the severity of symptoms and large fluctuations within an individual have been described (Zuetenhorst & Taal 2005). The specificity of 5HIAA is around 90%, but the reported sensitivity is 35–68% in patients with NENs (Bajetta *et al.* 1999, Zandee *et al.* 2016, Oberg *et al.* 2017). 5HIAA is mainly used as an indicator of hypersecretory activity in patients with NENs, especially in midgut NENs (Bajetta *et al.* 1999). Its prognostic value, however, is

limited. Some studies have related higher urinary 5HIAA levels with mortality (Janson *et al.* 1997), but these results were not reproduced by other studies (Korse *et al.* 2009a, Zandee *et al.* 2016). Its combination with other markers also failed to predict OS and for this reason 5HIAA determination is only recommended to assess carcinoid syndrome (Bhattacharyya *et al.* 2008).

Pancreatic peptide

Pancreatic peptide (PP) is a non-specific marker in NENs (Landry *et al.* 2014). Around 63% of pancreas NENs (PNENs) and 18–53% of primary gastrointestinal NENs show increased PP levels (Panzuto *et al.* 2004). Its determination does not seem to increase the diagnostic performance of other markers like CgA, but changes above 50% in PP serum levels seem to correlate with tumor increase on imaging (Walter *et al.* 2012).

Application of currently available biomarkers

Despite the above-mentioned limitations, current biomarkers are regularly used in clinical practice and their accuracy may increase when combined. Current evidence

Table 3 Sensitivity and specificity of current and novel neuroendocrine biomarkers.

Tumor marker	Primary tumor location	Sensitivity (%)	Specificity (%)
Chromogranin A (Schurmann <i>et al.</i> 1992, Bajetta <i>et al.</i> 1999, Seregini <i>et al.</i> 2001, Nolting <i>et al.</i> 2012, Duque <i>et al.</i> 2013, Wang <i>et al.</i> 2014, Oberg <i>et al.</i> 2017)	Non-specific	60–83	72–85
Urinary5-HIAA (Bajetta <i>et al.</i> 1999, Zandee <i>et al.</i> 2016, Oberg <i>et al.</i> 2017)	Midgut	35–68	90–100
Pancreatic polypeptide (Panzuto <i>et al.</i> 2004, Metz & Jensen 2008, Oberg <i>et al.</i> 2015)	Pancreas, midgut	31–63	~67
Neuron-specific enolase (Baudin <i>et al.</i> 1998, Bajetta <i>et al.</i> 1999, Oberg <i>et al.</i> 2015)	Non-specific	33	73
NT-proBNP (Oberg <i>et al.</i> 2015, Modlin <i>et al.</i> 2016)	Midgut (non-specific for CHD)	87	80
Pro-GRP (Korse <i>et al.</i> 2011)	Lung	43	99
PNMA2 (Cui <i>et al.</i> 2010)	SB-NENs	46–50	NDA
DCR (Edfeldt <i>et al.</i> 2017)	SB-NENs	AUC: 0.74	
TFF3 (Edfeldt <i>et al.</i> 2017)	SB-NENs	AUC: 0.72	
Midkine (Edfeldt <i>et al.</i> 2017)	SB-NENs	AUC: 0.71	
Multitranscript genes (Modlin <i>et al.</i> 2013, Kidd <i>et al.</i> 2015, Bodei <i>et al.</i> 2016)	GEP-NENs	75–98	

AUC, area under the curve; NDA, no data available.

suggests that circulating CgA levels should be measured at the diagnosis and during follow-up for evaluating disease course and for evaluating treatment response. NSE may be determined for the diagnosis and follow-up of neuroendocrine carcinomas and to predict outcome in NENs. u-5HIAA measurement is valuable for diagnosis, especially in midgut NENs, and when elevated, it should be determined during follow-up in which it might be used in combination with NT-proBNP (O'Toole *et al.* 2009, Niederle *et al.* 2016).

Importantly, specific comparisons between markers are difficult since several publications are based on heterogeneous cohorts and retrospective analysis. Additionally, the differences between the used assays limit comparisons and solid conclusions. Notwithstanding, several guidelines recommend these biomarkers for the diagnosis and follow-up in NENs (Table 2).

Potential novel diagnostic biomarkers

To improve early diagnosis and follow-up of NENs, several new prognostic and treatment-related biomarkers have been developed in recent years (Fig. 1). Most of them are still under study and not yet available for use in clinical practice. It is aimed to develop high-specific and sensitive circulating biomarkers using DNA, RNA and metabolomic approaches. Combination markers and multianalyte analysis may be more effective than the current use of monoanalytes because of a higher sensitivity (Modlin *et al.* 2013, 2015, Oberg *et al.* 2015), although validation is still needed. A summary of potential novel circulating and tissue biomarkers for diagnosis, prognosis and

therapy response prediction, as well as their relation with tumor localization, is shown in Fig. 2. Herein we describe the potential applicability of novel peptides/growth factors, DNA, RNA and therapeutic markers for NENs, in particular, circulating biomarkers.

Peptides and growth factors

Several peptides and growth factors (Table 4) have been studied for a (potential) role as biomarker in NENs and may (1) help to localize primary tumors (e.g. progastrin-releasing peptide in lung NENs, connective tissue growth factor (CCN2), paraneoplastic Ma antigen 2, DcR3, TFF3 and midkine in small intestine NENs (Bergestuen *et al.* 2010, Korse *et al.* 2011, Oberg *et al.* 2015, Edfeldt *et al.* 2017)); (2) predict the outcome in functioning NENs (e.g. α -Internexin in insulinomas (Schimmack *et al.* 2012, Liu *et al.* 2014)) or predict early complications in patients with CHD (CCN2 (Bergestuen *et al.* 2010)) and (3) add information to that provided by other circulating/tissue markers for treatment response evaluation and outcome prediction (e.g. pro-GRP and CgA for predicting outcome/therapeutic response in lung carcinoids; α -Internexin in combination with Ki67 for aggressiveness prediction in insulinomas (Grabowski *et al.* 2005, Korse *et al.* 2011, Fotouhi *et al.* 2016, Fujino *et al.* 2016) or as part of multianalytes tests (Edfeldt *et al.* 2017)).

Although imaging markers are not described in this review, it is important to mention that some peptides may be useful to correlate with imaging techniques. For instance, glucose transporter 1 (GLUT1) expression in NENs is associated with the Ki67 index and

Figure 1

Timeline of the publication of potential novel biochemical and therapeutic markers in neuroendocrine neoplasms during the last two decades. Monoanalytes, transcripts, DNA-, RNA- immune- markers are shown, mostly are still under study and not available for use in clinical practice. Image-based modalities are represented in purple. 18F-FDG PET, 18fluorodeoxyglucose positron emission tomography; ALT, alternative lengthening of telomeres; CCN2, connective tissue growth factor; CECs, circulating endothelial cells cftDNA, circulating cell-free tumor DNA; CTCs, circulating tumor cells; EGFR, epidermal growth factor receptor; GLUT-1, glucose transporters type 1; IL-8, interleukin 8; MGMT, O-6-methylguanine-DNA methyltransferase; miRNA, microRNA; MT, multitranscript; PD-L, programmed death ligand-1; PIGF, Placental growth factor; PNMA2, paraneoplastic Ma antigen 2; proGRP, progastrin-releasing peptide; SDF-1 α , stromal cell-derived factor 1 α ; TSC, Tuberous sclerosis complex; VEGFR, vascular endothelial growth factor receptor; XIAP, X-linked inhibitor of apoptosis. Imaging techniques, as reference, are presented in purple.

18-fluorodeoxyglucose (FDG) uptake at FDG-positron emission tomography (PET) scans (Binderup *et al.* 2013). GLUT-1 expression may serve as an additional marker for aggressiveness of NENs and may add to a more accurate grading (Binderup *et al.* 2013).

Although some of these peptides have been suggested as promising biomarkers, most of them are non-specific. In addition, their applicability is limited, due to their sensitivity and specificity (Table 3) and the absence of appropriate cut-off levels. In addition, some of them have

been described only in single retrospective studies; thus, further validation in larger and longitudinal cohorts is still required. A summary of potential peptide/growth factors markers for NENs is described in Table 4.

Genetic and epigenetic markers

Generally, tissue and circulating tumor DNA markers may provide information on the genetic characteristics of the tumor which may result in better prediction of clinical

Figure 2

Summary of potential novel diagnostic and therapeutic markers in neuroendocrine neoplasms. Several tumor or plasma/serum biomarkers seem to play a role in the diagnosis or follow-up in lung and GEP-NENs. Its presence may be determined in serum or tissue samples. Please refer to the text for explanation of each tumor marker. *specific for carcinoid heart disease; **only for lung NENs; ***only for small intestine NENs; ALT, alternative lengthening of telomeres; CCN2, connective tissue growth factor for carcinoid heart disease; CECs, circulating endothelial cells; cftDNA, circulating cell-free tumor DNA; EGFR, epidermal growth factor receptor; GLUT-1, glucose transporters type 1; MGMT, O-6-methylguanine-DNA methyltransferase; MT, multitranscript; PD-L, programmed death ligand-1; PIGF, placental growth factor; PNMA2, paraneoplastic Ma antigen 2; proGRP, progastrin-releasing peptide; SDF-1 α , stromal cell-derived factor 1 α ; SST, somatostatin; TSC, tuberous sclerosis complex; VEGFR, vascular endothelial growth factor receptor; XIAP, X-linked inhibitor of apoptosis.

Table 4 Peptides and growth factors as novel markers in NENs.

Peptide/growth factor	Function	Potential role as marker in NENs
Progastrin-releasing peptide (proGRP)	Precursor of gastrin-releasing peptide, a neuropeptide hormone widely distributed throughout the gastrointestinal and pulmonary tract (McDonald et al. 1979)	Primary tumor localization in patients with a metastatic NEN of unknown origin. Complementary marker to CgA in lung NEN for treatment response evaluation and survival (Korse et al. 2011, 2015)
Connective tissue growth factor for carcinoid heart disease (CCN2)	CCN2 is an early gene product of the CCN family of matricellular proteins, which are involved in cell proliferation, angiogenesis, tumorigenesis and wound healing. It may be involved in the pathogenesis of carcinoid heart disease (Holbourn et al. 2008, Bergestuen et al. 2010)	Independent predictor of both reduced right ventricular function and right-sided valve regurgitation (its plasma levels are inversely related to right ventricular function levels) Early predictor of cardiac fibrosis (Bergestuen et al. 2010)
Paraneoplastic Ma antigen 2 (PNMA2)	Antineuronal antibodies identified as markers of neurological paraneoplastic syndromes (Schuller et al. 2005)	Allows the identification of almost 50% of SB-NENs at the primary stage of the disease Correlation with disease progression and recurrence free survival (Cui et al. 2010)
α -Internexin	Cytoskeleton protein involved in tumorigenesis and disease progression (Nathke 2006)	Association with proliferation, ki67 index and malignancy (Schimmack et al. 2012)
X-linked inhibitor of apoptosis (XIAP)	Inhibitor of apoptotic cell death in cancer cells (Mihaly et al. 2014, Obexer & Ausserlechner 2014)	Potential target therapies (Yap et al. 2011, Cingarlini et al. 2012, Augeri et al. 2016)
Glucose transporters type 1 (GLUT-1)	Mediates the transport of glucose across the cellular membrane and are commonly overexpressed in tumors, probably related with higher metabolism and cell growth (Clavo et al. 1995)	Predictor of risk of death in neuroendocrine lung carcinomas and lung carcinoids (Ozbudak et al. 2009) Relation with Ki67 index in GEP- and lung NENs (Binderup et al. 2013, Benzerdjeb et al. 2017) Correlation with the uptake in 18-FDG-PET (Binderup et al. 2013)
DcR3	Regulates cytokines which influence tumor growth and reduce apoptotic stimuli (Lin & Hsieh 2011)	DcR3 correlates to liver metastasis and worse survival Predictor of treatment resistant tumors (Edfeldt et al. 2017)
TFF3	Protects and repairs epithelial surfaces Enhances migration, angiogenesis, and inhibits apoptosis (Vestergaard et al. 2010, Casado et al. 2012, Huang et al. 2013)	Higher concentrations have been correlated to reduced survival (Edfeldt et al. 2017)
Midkine	Promotes tumor cells migration, angiogenesis and reduces apoptosis (Jones 2014)	Predictive marker to chemotherapy response (Hu et al. 2010, Wu et al. 2015)

outcome and could aid in clinical decision making ([Modlin et al. 2014b](#)). The possibility of performing liquid biopsies is expected to anticipate malignancy of solid lesions in a non-invasive way, but it is still necessary to optimize the detection technique, analysis and interpretation.

An example of a tissue DNA prognostic marker for NENs involves alternative lengthening of telomeres (ALT). A telomerase-independent mechanism to avoid the chromosome end replication was suggested in tumor cells, and in this context, ALT was reported in liver metastasis of NENs ([Dogeas et al. 2014](#)). In PNENs, whole-exome sequencing studies have demonstrated that inactivating mutually exclusive mutations in X-linked transcriptional regulator (ATRX) and death domain-associated protein 6

(DAXX) genes ([Jiao et al. 2011](#)) are associated with the ALT ([Heaphy et al. 2011, Schwartzentruber et al. 2012](#)). However, results on its relationship with clinical features are inconclusive and in some cases contradictory. In this sense, ALT-positive PNENs have been associated with larger tumor size, grading, vascular/perineural invasion and metastasis ([Marinoni et al. 2014, Kim et al. 2017](#)). In addition, an increased risk of recurrence and decreased OS has been reported in ALT-positive NEN metastasis ([Marinoni et al. 2014, Kim et al. 2017](#)). In contrast, other authors found an association with better clinical outcomes ([Jiao et al. 2011, Dogeas et al. 2014](#)) including metastatic disease ([Kim et al. 2017](#)). Since it is possible to determine ALT, ATRX and DAXX using fine-needle

aspiration (FNA), they may be used as minimally invasive prognostic markers in NENs (VandenBussche *et al.* 2017), but their clinical significance should still be evaluated in detail.

Additionally, whole-genome sequencing in NENs allow the identification of genomic events related with tumor pathogenesis. In this sense, germline deleterious mutations affecting DNA damage repair in PNENs have been described (in the base-excision-repair *MUTYH* gene or the homologous recombination gene *BRCA2*) (Scarpa *et al.* 2017). Furthermore, mutations in genes involved in chromatin remodeling, DNA repair and mTOR signaling may also play a role in PNEN pathogenesis (Scarpa *et al.* 2017). Several publications have also shown chromosome losses affecting genes related to DNA repair or damage checkpoints (*VHL*, *MEN1*, *ATM*, *PTEN*) in PNENs (Capurso *et al.* 2012, Scarpa *et al.* 2017). In this sense, most recent reviews describe genetic alterations that are consistently related with the loss of *MEN1* function, the activation of the PI3K/mTOR pathway, changes in chromatin remodeling and telomeres alteration (Mafficini & Scarpa 2018).

Importantly, somatic mutations and deletions have also been described in midgut NENs, specifically in the cyclin-dependent kinase inhibitor gene *CDKN1B*. This finding suggests that the p21/p27/p53 family, which is involved in the cell cycle, may also be involved in the pathogenesis of small-bowel NENs (Francis *et al.* 2013). Genetic alterations in PNENs are extensively reviewed in a recent publication by Stevenson and colleagues (Stevenson *et al.* 2018).

Cell-free DNA (cftDNA) from liquid biopsies may become a biomarker in NENs, although to date, no studies have been published yet on the detection of cftDNA in NENs. cftDNA generally contains identical genetic defects as the primary tumor (Diaz & Bardelli 2014), is released after apoptosis (Francis & Stein 2015) and can be detected in serum (Marzese *et al.* 2013, Rothe *et al.* 2014). The analysis of cftDNA may be useful for early detection of (residual or recurrent) disease, to monitor tumor burden, to assess molecular heterogeneity and to predict PFS (Francis & Stein 2015), especially in adenocarcinomas (Francis & Stein 2015). Measurement of cftDNA might be a promising tool in NENs, but needs further investigation (Rizzo & Meyer 2018). The ultimate aim of cftDNA assessment would be to add to or replace tissue biopsies (Khan *et al.* 2013, Sikora *et al.* 2015). Prerequisites for cftDNA analysis are sufficient tumoral DNA release and the presence of tumor-related mutations to identify tumor DNA. These conditions may only be present in a subset of

NEN patients, thereby limiting the applicability of cftDNA measurement. Further study is needed to determine the potential role of cftDNA analysis in NEN.

A summary of genetic markers in NENs is shown in Fig. 3.

RNA markers

RNA markers are novel and potentially promising minimally invasive markers used for diagnostic purpose and/or to identify the therapeutic targets of NENs. Specifically, the identification of circulating target gene mRNAs using PCR amplification has been used for determining stage, prognosis, recurrence or new metastasis in several cancers (van't Veer *et al.* 2002, Frederiksen *et al.* 2003, Hess *et al.* 2006). Blood circulating- and tumor tissue-transcripts from GEP- and bronchopulmonary NENs are highly correlated (Cwikla *et al.* 2015, Kidd *et al.* 2015). Modlin *et al.* have developed a PCR-based molecular test using 51 genes for identifying GEP-NENs (Modlin *et al.* 2013). For this so-called NETest, a score, based on tissue and peripheral blood transcriptomes, was developed (Modlin *et al.* 2013) as a prognostic and follow-up tool for NENs (Modlin *et al.* 2013, 2014a, 2015, Kidd *et al.* 2015). NETest results were shown to differentiate progressive disease (Kidd *et al.* 2015) and predict tumor response to somatostatin analogs (SSAs) (Cwikla *et al.* 2015). Further prospective validation of this test is awaited.

Additionally, dysregulated miRNAs have been correlated with diagnosis, staging, progression, prognosis and therapeutic response in several tumors, including NENs (Di Leva & Croce 2013). miRNAs are endogenous, small (19–25 nucleotides), non-coding RNAs that regulate post-transcriptional gene expression by binding to mRNA molecules, and they probably modulate the expression of at least one-third of protein-coding genes (Demes *et al.* 2016). miRNAs have the capacity to target different genes implicated in the same pathway and/or in interacting pathways, allowing for the possibility of developing directed therapies that could silence several tumor pathways (Reddy 2015).

Specific patterns of miRNA expression may distinguish tumor tissue from normal tissue and acinar tumors from PNENs (Roldo *et al.* 2006, Vicentini *et al.* 2014). Some miRNAs are upregulated in PNENs (miR-140, miR-210), small-bowel (SB-)NENs (miR-96, miR-182, miR-183, miR-196a, miR-200a) and lung carcinoids (mMR-34a) (Li *et al.* 2013, Demes *et al.* 2016). Also, the downregulation of miRNA-133a, miRNA-1 and miRNA-143-3p has been demonstrated in metastasis when compared to the

Figure 3

Summary of genetic markers in pancreatic neuroendocrine neoplasms. Genetic markers are presented in green. Tumor cells release small fragments of cftDNA into circulation by multiple mechanisms, cftDNA contains identical genetic defects compared to the primary tumor. Mutations affecting chromatin remodeling and MEN1 function may be related to tumor proliferation. Inactivating mutations in ATRX and DAXX genes are associated with ALT. ALT, alternative lengthening of telomeres; ATRX, X-linked transcriptional regulator; cftDNA, cell-free tumor DNA; DAXX, death domain-associated protein 6.

primary NEN tumor (Ruebel *et al.* 2010, Miller *et al.* 2016). As prognostic marker, miRNA levels have been correlated with Ki-67 (Thorns *et al.* 2014, Arvidsson *et al.* 2018), degree of malignancy (e.g. miR-21 in PNENs; miR-13/miR-204-5p in SB-NENs) (Demes *et al.* 2016, Arvidsson *et al.* 2018) and OS (e.g. the downregulation of miR-375 in SB-NENs (Arvidsson *et al.* 2018)).

miRNAs may also be used for therapeutic goals, for example, inhibition of oncogenic miRNA expression or the introduction of a tumor suppressor miRNA (Vicentini *et al.* 2014). However, the currently available technology is not robust enough to support diagnostic or therapeutic use of miRNAs yet (Oberg *et al.* 2016). Furthermore, dysregulation of miRNAs is not tumor specific and the absence of cut-off levels for differentiating tissue and tumor subtypes, the lack of reproducibility in other NEN cohorts and the difficulties in their interpretation, currently limit their clinical application. Further studies are required to evaluate the application of miRNAs as clinical and therapeutic markers in NENs. This issue is extensively reviewed in recent publications (Zatelli *et al.* 2017, Zimmermann *et al.* 2018, Rizzo & Meyer 2018, Panarelli *et al.* 2019).

Potential novel diagnostic-therapeutic biomarkers

Some (potential) circulating and tissue therapeutic markers are available in NENs. To a certain extent, the currently available markers CgA and NSE can be used for treatment monitoring. Variations in serum CgA levels

after treatment with SSAs and PRRT have been reported. Specifically, decreased CgA in stable/responsive tumors has been observed (Caplin *et al.* 2014, van der Zwan *et al.* 2015), but serum CgA may also increase (>20%) due to radiation-induced cell damage or lysis after the first cycle of PRRT. In the latter case, this increase was followed by declined levels usually after 12 weeks (Brabander *et al.* 2017). Furthermore, tumor shrinkage has been associated with CgA or NSE response after treating patients with everolimus (increased PFS in patients with early CgA/NSE response) (Li *et al.* 2011). However, specific cut-off values to define response to different treatment modalities have not been determined yet and novel/specific therapeutic biomarkers are still required. A summary of clinical applicability of novel biomarkers in NENs is presented in Table 5.

Somatostatin receptor expression

Somatostatin receptor (SST) expression by NENs, in particular subtype 2, is used for imaging to diagnose and stage NENs (Wong *et al.* 2012) and is considered to have therapeutic implications for treatment with SSAs and PRRT with radiolabeled somatostatin analogs as Lutetium-177- or Yttrium-90-coupled analogs (Kwekkeboom *et al.* 2010, Strosberg *et al.* 2017). SST expression as imaging marker is not described in this review, but it has been comprehensively evaluated in several publications (de Herder *et al.* 2006, Kwekkeboom *et al.* 2010, Kunikowska *et al.* 2017, Bodei & Weber 2018, Hope *et al.* 2018).

SST can also be evaluated in NEN tissue samples using immunohistochemistry and qPCR (Fig. 4; Righi *et al.* 2010, Mizutani *et al.* 2012, Lambertini *et al.* 2013, Kanakis *et al.* 2015, Herrera-Martínez *et al.* 2017, 2018). SST expression may help to differentiate normal and tumor tissue in lung carcinoids and GEP-NENs and has been related to vascular/nerve invasion and metastasis (Herrera-Martínez *et al.* 2017, 2018). The tumor SST expression profile may also be helpful for predicting treatment response (Reubi *et al.* 2010, Righi *et al.* 2010), especially in aggressive cases (Righi *et al.* 2010). On the other hand, the immunohistochemical assessment of NEN tissue expression of SST subtype 2 had no additional value compared to the uptake on the OctreoScan in predicting tumor response after PRRT (Korner *et al.* 2012, Bison *et al.* 2014, van Adrichem *et al.* 2016a). The tumoral expression of SST3 and SST5 may also be a relevant marker supporting the potential benefit of novel SSAs. Truncated isoforms of SST can also be expressed by NENs, and their presence is associated with aggressive features

Table 5 Clinical applicability of potential new biomarkers in NENs.

Clinical diagnosis	Function	
	Therapeutic role	Prognostic role
ALT	ALT(?)	ALT*
cftDNA	SST expression	Somatic/germline mutations*
microRNAs	MGMT	cftDNA*
SST expression	VEGF	microRNAs***
PIGF (?)	IL-8 (?)	SST expression***
proGRP	PD-1/PD-L1	MGMT**
CCN2	XIAP	EGFR**
PNMA2		VEGF*
DcR3		IL-8***
		(SDF)-1 α ***
		PIGF***
		TSC**
		PD-1/PD-L1***
		proGRP with CgA*
		CCN2*
		PNMA2*
		α -Internexin*
		GLUT-1*
		DcR3, TFF3, midkine***

*Disease course predictor; **Intervention outcome predictor; ***Disease and treatment predictor.

ALT, alternative lengthening of telomeres; CCN2, connective tissue growth factor for carcinoid heart disease; cftDNA, cell-free DNA; CTCs, circulating tumor cells; EGFR, epidermal growth factor receptor; GLUT-1, glucose transporters type 1; IL-8, interleukin-8; MGMT, O-6-methylguanine-DNA methyltransferase; PD-1, programmed death-1; PD-L1, programmed death ligand 1; PIGF, placental growth factor; PNMA2, paraneoplastic Ma antigen 2; proGRP, progastrin-releasing peptide; SDF-1 α , stromal cell-derived factor-1 α ; SST, somatostatin receptor; VEGF, vascular endothelial growth factor; XIAP, X-linked inhibitor of apoptosis.

(Sampedro-Nunez *et al.* 2016). Unfortunately, results are based on retrospective heterogeneous cohorts, which may limit the reproducibility. Additionally, in some of the above indicated studies, SST expression by qPCR was determined in formalin-fixed paraffin embedded tumors, which may affect the expression profile in some samples (Sampedro-Nunez *et al.* 2016, Herrera-Martínez *et al.* 2017, 2018).

O-6-methylguanine-DNA methyltransferase (MGMT)

An example of a tissue DNA therapeutic marker for NENs is the methylation pattern of the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT). Several agents have antitumor effects by inducing DNA methylation at the O6 position of guanine, resulting in apoptosis and tumor cell death (Liu & Gerson 2006). Those lesions can be restored by MGMT, reduction of which may increase the sensitivity of tumor cells to alkylation-induced DNA damage (Christmann *et al.* 2011). The methylation of MGMT promoter and loss of MGMT protein expression have been reported in GEP-NENs (Walter *et al.* 2015). Decreased MGMT expression has been associated to tumor sensitivity to alkylant-based chemotherapy agents, for example, temozolomide, alone or in combination therapy (Gerson 2002). In PNENs, absence of MGMT is more common compared to intestinal or lung carcinoids, which explains the better treatment response in PNENs to temozolomide (Kulke *et al.* 2009, Schmitt *et al.* 2014).

Further, a 'hypermethylator' phenotype, which is characterized by the presence of a high number of methylated genes, has been associated with more progressive disease and shorter survival (Walter *et al.* 2015), whereas this association was not found in well-differentiated PNENs (Raj *et al.* 2017). The predictive value of MGMT status for treatment response in NENs will be evaluated in clinical trials with alkylating agents (NCT03217097).

Molecular biomarkers for treatment with tyrosine kinase inhibitors (TKIs)

In patients with advanced, well-differentiated, progressive PNENs, sunitinib can induce tumor stabilization and improve PFS. Currently, sunitinib is used for progressive disease, but its combination with SSAs, chemotherapeutic agents or neo-adjuvant or adjuvant therapy in earlier stages of resectable PNENs has also been proposed (Delbaldo *et al.* 2012, Mateo *et al.* 2012). The possibility to peripherally measure monoanalytes directly related to

Figure 4

Somatostatin receptors expression for diagnosis. SST expression may be determined in tumor using immunochemistry (sst2 immunostaining in a GEP-NEN; right panel) and/or RT-qPCR (SST subtype mRNA profile in an exemplary GEP-NEN; left panel). Both results may be used for treatment decisions but also to predict outcome. SST, somatostatin.

the drug mechanism of action represents an important approach to predict treatment response; in this sense, some molecular biomarkers have been examined in the last years.

Epidermal growth factor receptor

The epidermal growth factor receptor (EGFR) is overexpressed in non-small-cell lung cancer and an increased sensitivity to the TKIs erlotinib and gefitinib has been reported when the tyrosine kinase domain of the EGFR has somatic mutations (Paez *et al.* 2004). EGFR expression by immunohistochemistry was demonstrated in 21–28% of typical carcinoids, 29–57% of atypical lung carcinoids (Rusch *et al.* 1996, Rickman *et al.* 2009) and in 40–96% of NENs, while its gene amplification by fluorescent *in situ* hybridization was observed in 55% of cases (Srivastava *et al.* 2001, Shah *et al.* 2006, Rickman *et al.* 2009, Gilbert *et al.* 2010). In addition, activating EGFR mutations have been described in NENs and may be associated with improved treatment response (Costanzo *et al.* 2013, Aroldi *et al.* 2014). Importantly, EGFR mutations are rare in GEP-NENs, and their clinical relevance may be limited as compared with other tumors including lung adenocarcinoma (Park *et al.* 2016). The specific clinical significance of the expression of EGFR, however, is still to be determined.

Vascular endothelial growth factor receptor

Vascular endothelial growth factor (VEGF) is the most important regulatory factor of tumor angiogenesis and has been related to cell survival, growth and metastasis (Niu & Chen 2010). VEGF may be determined in tumor and in FNA samples (Angelescu *et al.* 2013). In general, well-differentiated GEP-NENs express high levels of VEGF and its transmembrane receptors ((VEGFR-1, VEGFR-2,

VEGFR-3) (Pavel *et al.* 2005)), which can be detected in peripheral blood (Mateo *et al.* 2012). In this context, a worse clinical course has been reported in NENs with increased VEGF expression (Terris *et al.* 1998, Pavel *et al.* 2005, Zhang *et al.* 2007, Yao *et al.* 2011). Immunohistochemical and molecular expression of VEGFR-1/-2 has been reported in over 50% of GEP-NENs (La Rosa *et al.* 2003, Angelescu *et al.* 2013) without being directly related to tumor malignancy (La Rosa *et al.* 2003).

Some relations between VEGFR and patient outcome have been described; specifically, low VEGFR-1 levels have been related to longer PFS (Yao *et al.* 2012), high baseline VEGFR-2 levels to decreased OS in PNENs (Zurita *et al.* 2015) and low VEGFR-3 levels to longer PFS/OS in carcinoid patients (Zurita *et al.* 2015). Increased VEGF concentrations accompanied by decreased VEGFR-2 and VEGFR-3 levels have been reported after treatment with sunitinib (Deprimo *et al.* 2007), but their levels returned to baseline during the off-treatment period (Zurita *et al.* 2015). Unfortunately, VEGFRs are not tumor specific; additionally, cut-off levels are also necessary to predict outcome. The applicability of VEGFR-1 as a therapeutic predictive marker is currently considered in clinical trials (pazopanib in advanced NENs, NCT01280201), but further studies are still required.

Interleukin-8

Interleukin-8 (IL-8) has proangiogenic, mitogenic and motogenic effects through the activation of the receptors CXCR1 and CXCR2 (Mateo *et al.* 2012). PNENs overexpress not only IL-8 but also its receptor CXCR2 (Tecimer *et al.* 2000, Hussain *et al.* 2010). IL-8 seems to be increased in progressive NENs, while lower IL-8 baseline levels have been associated with longer survival (Pavel *et al.* 2005). Patients with SB-NENs and lower IL-8 levels were shown to

have disease stabilization or clinical response to sunitinib (Bello *et al.* 2006). It has also been hypothesized that monitoring IL-8 in plasma during sunitinib treatment could be useful to predict drug resistance (Huang *et al.* 2010), but this needs further investigation.

Stromal cell-derived factor (SDF)-1 α

SDF-1 α plays a role in cell migration, proliferation, survival and angiogenesis (Mateo *et al.* 2012) and is the natural ligand of CXCR4. CXCR4 has been reported in several cancer types (Balkwill 2004), seems to be involved in tumor progression, metastasis, hypoxia adaptation and stem cell survival (Kaemmerer *et al.* 2015) and may serve as a marker of tumor activity and progression (Zurita *et al.* 2015). SDF-1 α expression seems to be increased in PNENs compared to other NENs and is inversely correlated with time to disease progression (Zurita *et al.* 2015). In addition, it has been described as a circulating biomarker associated with tumor response to sunitinib (Antonuzzo *et al.* 2013). Arvidsson and collaborators described downregulation of SDF-1 α and upregulation of CXCR4 in hypoxic carcinoid cells with consequently higher cell migration, probably due to the activation of the mitogen-activated protein kinase pathway. Based on this, a putative role in antiangiogenic drugs resistance was also suggested, and SDF-1 α may serve as a therapeutic target (Arvidsson *et al.* 2010).

Circulating tumor, endothelial and white cells

Circulating tumor cells (CTCs) have been widely used in several tumors as peripheral blood tumor markers (Cristofanilli *et al.* 2005, Cohen *et al.* 2008, Resel Folkersma *et al.* 2012). The identification of cellular expression of the epithelial cell adhesion molecule (EpCAM) allowed the determination of CTCs in NENs (Modlin *et al.* 2016), in which a threshold of 1 CTC (similarly to breast cancer) was demonstrated (Khan *et al.* 2011). CTCs have been associated with higher tumor grade and burden, increased circulating CgA, Ki67 index and worse PFS and OS in grade 1–2 NENs (Khan *et al.* 2011, 2013). Measurement and molecular characterization of CTCs may be helpful to stratify patients for specific therapies in the future (Khan *et al.* 2011, Zatelli *et al.* 2017). However, the sensitivity of CTCs varies according to the NEN type, and CTCs are not specific for any subgroup of tumors (Oberge *et al.* 2015).

Additionally, circulating endothelial cells (CECs) were also described in NENs, specifically two different subpopulations: endothelial precursors derived from the bone marrow (CEPs) and mature CECs (Nolan *et al.* 2007).

Increased circulating CECs have been related to vessel damage during antiangiogenic treatment and consequently with a longer PFS (Beaudry *et al.* 2005). Theoretically, CEPs should decrease after anti-VEGF therapy (Kalka *et al.* 2000); but in contrast, decreased CECs and stable CEPs were observed in NENs after the first cycle of treatment with sunitinib (Zurita *et al.* 2015).

Moreover, myeloid cells have been related to angiogenesis, disease progression, metastasis and the expression of some receptors related with the VEGF and SDF-1 α pathways in other tumors (Fernandez Pujol *et al.* 2000, Condeelis & Pollard 2006). Zurita *et al.* described decreased CD14+ monocytes expressing VEGFR-1 and CXCR4 in NENs treated with sunitinib. It has been postulated that possible relations exist between specific monocyte subpopulations and drug pharmacodynamics, which would be useful as a treatment response predictor (Zurita *et al.* 2015). Because of the heterogeneity of the included patient samples (grading, previous treatments and origin of primary tumor), results remain controversial (Antonuzzo *et al.* 2013). Currently, there is no consensus for supporting the use of CTCs or CECs as an indicator of tumor burden or parameter of treatment response in NENs (Oberge *et al.* 2016). Further prospective, longitudinal studies in this field are still required. A summary of current tumor biomarkers for TKIs is shown in Fig. 5.

Molecular biomarkers for mTOR pathway inhibitors

Increased PFS has been described in patients with advanced metastatic PNENs treated with the mTOR pathway inhibitor everolimus (Yao *et al.* 2010, Pavel *et al.* 2011). Although the combination of everolimus and SSAs does not seem to increase OS, the heterogeneity of the included patients makes these results inconclusive (Pavel *et al.* 2017). Based on this, it would be valuable to develop markers that could early identify those patients who may benefit from everolimus alone or in combination with SSAs.

In this sense, placental growth factor (PIGF) has been related to angiogenesis, tumor burden, presence of metastases and survival (Carmeliet *et al.* 2001, Fischer *et al.* 2008) and is thought to reflect the activation of AKT and ERK pathways (Parr *et al.* 2005, Fischer *et al.* 2008, Wei *et al.* 2009). Elevated levels of circulating PIGF have been demonstrated in PNENs, with increasing levels from grade 1 to grade 3 tumors (Hilfenhaus *et al.* 2013). Decreased circulating PIGF was observed after treatment with everolimus in the RADIANT-III study (Hilfenhaus *et al.* 2013). PIGF levels reflect tumor aggressiveness

Figure 5

Therapeutic markers: molecular biomarkers for tyrosine kinase and mTOR inhibitors. Blue arrows represent the effect of the mTOR inhibitor everolimus and red arrows the effect of the tyrosine kinase inhibitor sunitinib. Molecular markers are presented in blue. Response to sunitinib has been related to decreased SDF1, IL-8, VEGFR 2-3, CD14 monocytes expressing VEGFR, decreased CEPs, increased CECs and probably decreased PIGF. Response to everolimus has been related to decreased PIGF and VEGFR2. Factors related to progression-free survival (PFS) and OS are also shown. CECs, circulating endothelial cells; CPECs, circulating endothelial precursors derived from the bone marrow; CXCR 1,2,4, chemokine family receptor 1,2,4; IL-8, interleukin-8; PIGF, placental growth factor; SDF-1 α , stromal cell-derived factor 1 α ; TSC 1-2, tuberous sclerosis complex 1-2; VEGF, vascular endothelial growth factor; VEGFR 1-3, vascular endothelial growth factor receptor 1-3.

(Hilfenhaus *et al.* 2013), whereas others studies suggest that PlGF may also induce the formation of vascular networks that are hypersensitive to anti-VEGF therapy (Hedlund *et al.* 2013). Tumor-derived PlGF was postulated to become a potential predictive marker of anti-VEGF therapy (Hedlund *et al.* 2013).

As previously described for TKIs markers, midgut NENs and PNENs overexpress VEGF and its receptors (Christofori *et al.* 1995, Terris *et al.* 1998, La Rosa *et al.* 2003). In the RADIANT-III trial, a significantly progressive reduction in VEGFR-2 was observed after treatment with everolimus (Yao *et al.* 2012), but the specific clinical relevance and applicability in NENs must still be determined.

In addition, it has been suggested that mTOR-directed therapies may be more effective in tumors with tuberous sclerosis complex 1 (TSC1) somatic mutation, which acts as a regulator of mTOR pathway activation (Iyer *et al.* 2012). TSC is an autosomal dominant multisystem disorder caused by mutations of two tumor suppressor genes, TSC1 and TSC2, which encode for hamartin and tuberin, respectively. The interaction between these proteins is critical for cell growth and proliferation (Dworakowska & Grossman 2009). Additionally, mutations in TSC2 have been described in PNENs with more aggressive features and progressive disease (Bombardieri *et al.* 2013). A schematic overview of current tumor biomarkers for mTOR inhibitors and TKIs is shown in Fig. 5.

Biomarkers for immune therapy

Programmed death-1 (PD-1) is expressed on T-, B- and myeloid cells and downregulates the activation of T-cells in tumors. The programmed death ligand 1 (PD-L1) and PD-1 are overexpressed in tumor-infiltrating lymphocytes in several types of cancer (Dong *et al.* 1999, Freeman *et al.* 2000, Lyford-Pike *et al.* 2013, He *et al.* 2015). PD-1 and PD-L1 induce lymphocyte apoptosis and cytokine secretion, which is crucial in tumor immunosuppression (Fan *et al.* 2016).

Initially, PD-L1 was described in SCLC (Schultheis *et al.* 2015), in lung typical-atypical carcinoids and in large cell neuroendocrine carcinoma (Tsuruoka *et al.* 2017). Subsequently, its presence was described and related with clinical features in other NENs; specifically, PDL-1 has been correlated with tumor stage and histological type in PNENs, as well as with worse survival (Fan *et al.* 2016). In GEP-NENs, PD-L1 has been related with more proliferative and aggressive tumors (Ghebeh *et al.* 2006, 2007, Sabatier *et al.* 2015, Kim *et al.* 2016), probably related to a higher immunogenicity in proliferative tumor

cells (Kim *et al.* 2016). Despite PDL-1 and tumor grading being associated in GEP-NENs, no specific relation with the site of origin has been established (Kim *et al.* 2016). Some studies have reported an antitumor effect by drugs targeting PD-1 (nivolumab and pembrolizumab) and PD-L1 (MPDL3280A and BMS- 936559) (Ohaegbulam *et al.* 2015), especially in non-SCLC, which seems to be correlated to PD-L1 overexpression in the tumor (Powles *et al.* 2014). Unfortunately, the applicability in well-differentiated NENs seems to be limited, however. Further studies are required, especially focusing in the relation of PD-L1 expression and response rate in poorly differentiated NENs and carcinomas (Roberts *et al.* 2017).

Conclusions and future directions

The currently available biomarkers for NENs have important limitations, and there is an unmet need for accurate biomarkers that can be used for NEN diagnosis, prognosis and follow-up, therapy stratification and evaluation of treatment response. Currently, several prospective trials are evaluating the effect of novel therapeutic strategies in NENs (⁹⁰Yt-labeled microspheres, lenvatinib, palbociclib, tremelimumab, bevacizumab, temozolomide, pasireotide, PDR001) and most trials include the evaluation of treatment-related follow-up markers. To date, these new biomarkers include peptides/growth factors, DNA/RNA markers and CTCs.

Circulating markers, as well as, low-invasive techniques for early diagnosis (of disease and related complications) would be valuable to identify a personalized therapeutic sequence and follow-up. Circulating/tissue markers that could predict treatment response could assist to improve treatment-induced PFS. Finally, the combination of markers that enable to better predict the course of the disease, would also allow for better decision making with regard to the therapeutic strategy with the available different treatment options. In this respect, multianalyte measurement based on tumor genomics seems a promising tool for early outcome stratification and decision making. The development of blood-based analysis and liquid biopsy would represent non-invasive methods for diagnosis and prognosis as well. Additional validation studies will establish the definite role for this test. Other new parameters like cfDNA, miRNAs and CTCs and markers that predict response to TKIs and mTOR inhibitors need further investigation before clinical application is possible. Development and validation of novel biomarkers that improve diagnosis, assessment of tumor load, prediction of disease course,

prognosis and outcome of intervention is still a challenge. In this context, genomics may represent the basis for developing multitranscript biomarkers, additionally, the combination of several markers (that provide multifaceted information), may offer better medical management and use of resources in order to improve diagnosis, treatment, quality of life and survival in NEN patients.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References

- Angelescu R, Burada F, Angelescu C, Gheonea DI, Iordache S, Mixich F, Ioana M & Saftoiu A 2013 Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis. *Endoscopic Ultrasound* **2** 86–91. (<https://doi.org/10.4103/2303-9027.117692>)
- Antonuzzo L, Meoni G & Di Costanzo F 2013 Are circulating tumor cells a new, valid prognostic marker in neuroendocrine tumors? *Journal of Clinical Oncology* **31** 2518. (<https://doi.org/10.1200/JCO.2013.49.2132>)
- Ardill JE & O'Dorisio TM 2010 Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. *Endocrinology and Metabolism Clinics of North America* **39** 777–790. (<https://doi.org/10.1016/j.ecl.2010.09.001>)
- Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Muller HH & Barth P 2008 Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. *Clinical Gastroenterology and Hepatology* **6** 820–827. (<https://doi.org/10.1016/j.cgh.2008.02.052>)
- Aroldi F, Bertocchi P, Meriggi F, Abeni C, Oglisi C, Rota L, Zambelli C, Bna C & Zaniboni A 2014 Tyrosine kinase inhibitors in EGFR-mutated large-cell neuroendocrine carcinoma of the lung? A case report. *Case Reports in Oncology* **7** 478–483. (<https://doi.org/10.1159/000365413>)
- Arvidsson Y, Bergstrom A, Arvidsson L, Kristiansson E, Ahlman H & Nilsson O 2010 Hypoxia stimulates CXCR4 signalling in ileal carcinoids. *Endocrine-Related Cancer* **17** 303–316. (<https://doi.org/10.1677/ERC-09-0085>)
- Arvidsson Y, Rehammar A, Bergstrom A, Andersson E, Altiparmak G, Sward C, Wangberg B, Kristiansson E & Nilsson O 2018 miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival. *Modern Pathology* **31** 1302–1317. (<https://doi.org/10.1038/s41379-018-0010-1>)
- Augeri DJ, Langenfeld E, Castle M, Gilleran JA & Langenfeld J 2016 Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death. *Molecular Cancer* **15** 27. (<https://doi.org/10.1186/s12943-016-0511-9>)
- Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E & Bombardieri E 1999 Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. *Cancer* **86** 858–865. ([https://doi.org/10.1002/\(SICI\)1097-0142\(19990901\)86:5<858::AID-CNCR23>3.0.CO;2-8](https://doi.org/10.1002/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8))
- Balkwill F 2004 Cancer and the chemokine network. *Nature Reviews Cancer* **4** 540–550. (<https://doi.org/10.1038/nrc1388>)
- Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA & Bloom SR 2003 Pancreatic polypeptide reduces appetite and food intake in humans. *Journal of Clinical Endocrinology and Metabolism* **88** 3989–3992. (<https://doi.org/10.1210/jc.2003-030630>)
- Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffie P, *et al.* 1998 Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. *British Journal of Cancer* **78** 1102–1107. (<https://doi.org/10.1038/bjc.1998.635>)
- Baudin E, Bidart JM, Bachelot A, Ducreux M, Elias D, Ruffie P & Schlumberger M 2001 Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. *Annals of Oncology* **12** (Supplement 2) S79–S82. (https://doi.org/10.1093/annonc/12.suppl_2.S79)
- Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J & Heymach JV 2005 Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. *Clinical Cancer Research* **11** 3514–3522. (<https://doi.org/10.1158/1078-0432.CCR-04-2271>)
- Bello CL, Deprimo SE, Friece C, Smeraglia J, Sherman L, Tye L, Baum C, Meropol NJ, Lenz H & Kulke MH. 2006 Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. *Journal of Clinical Oncology* **24** (18 Supplement) abstract 4045.
- Benzerdjeb N, Berna P & Sevestre H 2017 GLUT1: A novel tool reflecting proliferative activity of lung neuroendocrine tumors? *Pathology International* **67** 32–36. (<https://doi.org/10.1111/pin.12486>)
- Bergsetuen DS, Gravning J, Haugaa KH, Sahakyan LG, Aakhus S, Thiis-Evensen E, Oie E, Aukrust P, Attramadal H & Edvardsen T 2010 Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors. *BMC Cancer* **10** 6. (<https://doi.org/10.1186/1471-2407-10-6>)
- Bhattacharyya S, Toumpanakis C, Caplin ME & Davar J 2008 Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. *American Journal of Cardiology* **102** 938–942. (<https://doi.org/10.1016/j.amjcard.2008.05.047>)
- Binderup T, Knigge UP, Federspiel B, Sommer P, Hasselby JP, Loft A & Kjaer A 2013 Gene expression of glucose transporter 1 (GLUT1), hexokinase 1 and hexokinase 2 in gastroenteropancreatic neuroendocrine tumors: correlation with F-18-fluorodeoxyglucose positron emission tomography and cellular proliferation. *Diagnostics* **3** 372–384. (<https://doi.org/10.3390/diagnostics3040372>)
- Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJM, Kwekkeboom DJ & de Jong M 2014 Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. *Clinical and Translational Imaging* **2** 55–66. (<https://doi.org/10.1007/s40336-014-0054-2>)
- Bodei L & Weber WA 2018 Somatostatin receptor imaging of neuroendocrine tumors: From agonists to antagonists. *Journal of Nuclear Medicine* **59** 907–908. (<https://doi.org/10.2967/jnumed.117.205161>)
- Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, Kwekkeboom DJ, Krenning EP, Baum RP & Paganelli G 2016 Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor

- radionuclide therapy (PRRT) in neuroendocrine tumors. *European Journal of Nuclear Medicine and Molecular Imaging* **43** 839–851. (<https://doi.org/10.1007/s00259-015-3250-z>)
- Bombardieri R, Moavero R, Roberto D, Cerminara C & Curatolo P 2013 Pancreatic neuroendocrine tumor in a child with a tuberous sclerosis complex 2 (TSC2) mutation. *Endocrine Practice* **19** e124–e128. (<https://doi.org/10.4158/EP13010.CR>)
- Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC, *et al.* 2010 The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, ileum, Appendix, and cecum. *Pancreas* **39** 753–766. (<https://doi.org/10.1097/MPA.0b013e3181ebb2a5>)
- Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, Krenning EP & Kwekkeboom DJ 2017 Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate. *Endocrine-Related Cancer* **24** 243–251. (<https://doi.org/10.1530/ERC-16-0524>)
- Caplin ME, Pavel M & Ruzsiewicz P 2014 Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *New England Journal of Medicine* **371** 1556–1557. (<https://doi.org/10.1056/NEJMc1409757>)
- Capurso G, Festa S, Valente R, Picicucci M, Panzuto F, Jensen RT & Delle Fave G 2012 Molecular pathology and genetics of pancreatic endocrine tumours. *Journal of Molecular Endocrinology* **49** R37–R50. (<https://doi.org/10.1530/JME-12-0069>)
- Carmeliet P, Moons L, Luttun A, Vincenti V, Compernelle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, *et al.* 2001 Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nature Medicine* **7** 575–583. (<https://doi.org/10.1038/87904>)
- Casado E, Garcia VM, Sanchez JJ, Gomez Del Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno Rubio J, Lopez RAB, Garcia-Cabezas MÁ, *et al.* 2012 Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target. *International Journal of Radiation Oncology, Biology, Physics* **84** 1151–1158. (<https://doi.org/10.1016/j.ijrobp.2012.01.083>)
- Christmann M, Verbeek B, Roos WP & Kaina B 2011 O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. *Biochimica et Biophysica Acta* **1816** 179–190. (<https://doi.org/10.1016/j.bbcan.2011.06.002>)
- Christofori G, Naik P & Hanahan D 1995 Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. *Molecular Endocrinology* **9** 1760–1770. (<https://doi.org/10.1210/mend.9.12.8614412>)
- Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R & De Apollonia L 2003 Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. *Annals of Oncology* **14** 1135–1141. (<https://doi.org/10.1093/annonc/mdg279>)
- Cingarlini S, Bonomi M, Corbo V, Scarpa A & Tortora G 2012 Profiling mTOR pathway in neuroendocrine tumors. *Targeted Oncology* **7** 183–188. (<https://doi.org/10.1007/s11523-012-0226-9>)
- Clavo AC, Brown RS & Wahl RL 1995 Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. *Journal of Nuclear Medicine* **36** 1625–1632.
- Clift AK, Faiz O, Goldin R, Martin J, Wasan H, Liedke MO, Schloerick E, Malczewska A, Rindi G, Kidd M, *et al.* 2017 Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. *Endocrine Connections* **6** 71–81. (<https://doi.org/10.1530/EC-16-0114>)
- Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, *et al.* 2008 Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *Journal of Clinical Oncology* **26** 3213–3221. (<https://doi.org/10.1200/JCO.2007.15.8923>)
- Condeelis J & Pollard JW 2006 Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell* **124** 263–266. (<https://doi.org/10.1016/j.cell.2006.01.007>)
- Costanzo R, Montanino A, Di Maio M, Piccirillo MC, Sandomenico C, Giordano P, Daniele G, Franco R, Perrone F, Rocco G, *et al.* 2013 Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. *Expert Review of Anticancer Therapy* **13** 1207–1218. (<https://doi.org/10.1586/14737140.2013.845092>)
- Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, *et al.* 2005 Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. *Journal of Clinical Oncology* **23** 1420–1430. (<https://doi.org/10.1200/JCO.2005.08.140>)
- Cui T, Hurtig M, Elgue G, Li SC, Veronesi G, Essaghir A, Demoulin JB, Pelosi G, Alimohammadi M, Oberg K, *et al.* 2010 Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. *PLoS One* **5** e16010. (<https://doi.org/10.1371/journal.pone.0016010>)
- Cwikla JB, Bodei L, Kolasinska-Cwikla A, Sankowski A, Modlin IM & Kidd M 2015 Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. *Journal of Clinical Endocrinology and Metabolism* **100** E1437–E1445.
- D'Amico MA, Ghinassi B, Izzicupo P, Manzoli L & Di Baldassarre A 2014 Biological function and clinical relevance of chromogranin A and derived peptides. *Endocrine Connections* **3** R45–R54. (<https://doi.org/10.1530/EC-14-0027>)
- Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T & Yao JC 2017 Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. *JAMA Oncology* **3** 1335–1342. (<https://doi.org/10.1001/jamaoncol.2017.0589>)
- de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SWJ, van der Lely AJ & Krenning EP 2006 Somatostatin receptor imaging for neuroendocrine tumors. *Pituitary* **9** 243–248. (<https://doi.org/10.1007/s11102-006-0270-5>)
- Delbaldo C, Faivre S, Dreyer C & Raymond E 2012 Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential. *Therapeutic Advances in Medical Oncology* **4** 9–18. (<https://doi.org/10.1177/1758834011428147>)
- Demes M, Aszyk C, Bartsch H, Schirren J & Fisseler-Eckhoff A 2016 Differential miRNA-expression as an adjunctive diagnostic tool in neuroendocrine tumors of the lung. *Cancers* **8** 38. (<https://doi.org/10.3390/cancers8040038>)
- Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD & Motzer RJ 2007 Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. *Journal of Translational Medicine* **5** 32. (<https://doi.org/10.1186/1479-5876-5-32>)
- Di Leva G & Croce CM 2013 miRNA profiling of cancer. *Current Opinion in Genetics and Development* **23** 3–11. (<https://doi.org/10.1016/j.gde.2013.01.004>)
- Diaz LA, Jr & Bardelli A 2014 Liquid biopsies: genotyping circulating tumor DNA. *Journal of Clinical Oncology* **32** 579–586. (<https://doi.org/10.1200/JCO.2012.45.2011>)
- Dogeas E, Karagkounis G, Heaphy CM, Hirose K, Pawlik TM, Wolfgang CL, Meeker A, Hruban RH, Cameron JL & Choti MA 2014 Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases. *Journal of the American College of Surgeons* **218** 628–635. (<https://doi.org/10.1016/j.jamcollsurg.2014.01.001>)

- Dong H, Zhu G, Tamada K & Chen L 1999 b7-h1 B7-H1, A third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nature Medicine* **5** 1365–1369. (<https://doi.org/10.1038/70932>)
- Duque M, Modlin IM, Gupta A & Saif MW 2013 Biomarkers in neuroendocrine tumors. *Journal of the Pancreas* **14** 372–376. (<https://doi.org/10.6092/1590-8577/1692>)
- Dworakowska D & Grossman AB 2009 Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. *Endocrine-Related Cancer* **16** 45–58. (<https://doi.org/10.1677/ERC-08-0142>)
- Edfeldt K, Daskalakis K, Backlin C, Norlen O, Tiensuu Janson E, Westin G, Hellman P & Stalberg P 2017 DcR3, TFF3 and midkine are novel serum biomarkers in small intestinal neuroendocrine tumors. *Neuroendocrinology* **105** 170–181. (<https://doi.org/10.1159/000452891>)
- Eskeland NL, Zhou A, Dinh TQ, Wu H, Parmer RJ, Mains RE & O'Connor DT 1996 Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. *Journal of Clinical Investigation* **98** 148–156. (<https://doi.org/10.1172/JCI118760>)
- Fan Y, Ma K, Wang C, Ning J, Hu Y, Dong D, Dong X, Geng Q, Li E & Wu Y 2016 Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. *OncoTargets and Therapy* **9** 6075–6082. (<https://doi.org/10.2147/OTT.S115054>)
- Fernandez Pujol B, Lucibello FC, Gehling UM, Lindemann K, Weidner N, Zuzarte ML, Adamkiewicz J, Elsasser HP, Muller R & Havemann K 2000 Endothelial-like cells derived from human CD14 positive monocytes. *Differentiation* **65** 287–300. (<https://doi.org/10.1046/j.1432-0436.2000.6550287.x>)
- Ferrari L, Seregni E, Lucignani G, Bajetta E, Martinetti A, Aliberti G, Pallotti F, Procopio G, Della Torre S, Luksch R, *et al.* 2004 Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. *International Journal of Biological Markers* **19** 295–304.
- Fischer C, Mazzone M, Jonckx B & Carmeliet P 2008 FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? *Nature Reviews Cancer* **8** 942–956. (<https://doi.org/10.1038/nrc2524>)
- Fotouhi O, Kjellin H, Larsson C, Hashemi J, Barriuso J, Juhlin CC, Lu M, Hoog A, Pastrian LG, Lamarca A, *et al.* 2016 Proteomics suggests a role for APC-survivin in response to somatostatin analog treatment of neuroendocrine tumors. *Journal of Clinical Endocrinology and Metabolism* **101** 3616–3627. (<https://doi.org/10.1210/jc.2016-2028>)
- Francis G & Stein S 2015 Circulating cell-free tumour DNA in the management of cancer. *International Journal of Molecular Sciences* **16** 14122–14142. (<https://doi.org/10.3390/ijms160614122>)
- Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, *et al.* 2013 Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. *Nature Genetics* **45** 1483–1486. (<https://doi.org/10.1038/ng.2821>)
- Frederiksen CM, Knudsen S, Laurberg S & Orntoft TF 2003 Classification of Dukes' B and C colorectal cancers using expression arrays. *Journal of Cancer Research and Clinical Oncology* **129** 263–271. (<https://doi.org/10.1007/s00432-003-0434-x>)
- Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, *et al.* 2000 Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *Journal of Experimental Medicine* **192** 1027–1034. (<https://doi.org/10.1084/jem.192.7.1027>)
- Fujino M, Aishima S, Shindo K, Oda Y, Morimatsu K, Tsutsumi K, Otsuka T, Tanaka M & Oda Y 2016 Expression of glucose transporter-1 is correlated with hypoxia-inducible factor 1 α and malignant potential in pancreatic neuroendocrine tumors. *Oncology Letters* **12** 3337–3343. (<https://doi.org/10.3892/ol.2016.5092>)
- Gao Y, Gao H, Wang G, Yin L, Xu W, Peng Y, Wu J, Jiang K & Miao Y 2018 A meta-analysis of prognostic factor of pancreatic neuroendocrine neoplasms. *Scientific Reports* **8** 7271. (<https://doi.org/10.1038/s41598-018-24072-0>)
- Gerson SL 2002 Clinical relevance of MGMT in the treatment of cancer. *Journal of Clinical Oncology* **20** 2388–2399. (<https://doi.org/10.1200/JCO.2002.06.110>)
- Ghebeh H, Mohammed S, Al-Omar A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, *et al.* 2006 The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. *Neoplasia* **8** 190–198. (<https://doi.org/10.1593/neo.05733>)
- Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T & Dermime S 2007 Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. *International Journal of Cancer* **121** 751–758. (<https://doi.org/10.1002/ijc.22703>)
- Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM & Ames MM 2010 Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. *Endocrine-Related Cancer* **17** 623–636. (<https://doi.org/10.1677/ERC-09-0318>)
- Grabowski P, Griss S, Arnold CN, Horsch D, Goke R, Arnold R, Heine B, Stein H, Zeitz M & Scherubl H 2005 Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. *Neuroendocrinology* **81** 1–9. (<https://doi.org/10.1159/000084892>)
- Grouzmann E, Gicquel C, Plouin PF, Schlumberger M, Comoy E & Bohuon C 1990 Neuropeptide Y and neuron-specific enolase levels in benign and malignant pheochromocytomas. *Cancer* **66** 1833–1835. ([https://doi.org/10.1002/1097-0142\(19901015\)66:8<1833::AID-CNCR2820660831>3.0.CO;2-9](https://doi.org/10.1002/1097-0142(19901015)66:8<1833::AID-CNCR2820660831>3.0.CO;2-9))
- Gut P, Czarnywojtek A, Fischbach J, Baczyk M, Ziennicka K, Wrotkowska E, Gryczynska M & Ruchala M 2016 Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. *Archives of Medical Science* **12** 1–9. (<https://doi.org/10.5114/aoms.2016.57577>)
- He J, Hu Y, Hu M & Li B 2015 Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. *Scientific Reports* **5** 13110. (<https://doi.org/10.1038/srep13110>)
- Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettgowda C, Rodriguez FJ, Eberhart CG, Hebbar S, *et al.* 2011 Altered telomeres in tumors with ATRX and DAXX mutations. *Science* **333** 425. (<https://doi.org/10.1126/science.1207313>)
- Hedlund EM, Yang X, Zhang Y, Yang Y, Shibuya M, Zhong W, Sun B, Liu Y, Hosaka K & Cao Y 2013 Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. *PNAS* **110** 654–659.
- Herrera-Martínez AD, Gahete MD, Sanchez-Sanchez R, Salas RO, Serrano-Blanch R, Salvatierra Á, Hofland LJ, Luque RM, Galvez-Moreno MA & Castano JP 2017 The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. *Lung Cancer* **109** 128–136. (<https://doi.org/10.1016/j.lungcan.2017.05.006>)
- Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Galvez-Moreno MA & Castano JP 2018 Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. *Endocrine* **59** 426–437. (<https://doi.org/10.1007/s12020-017-1482-3>)
- Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, *et al.* 2006 Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and

- cyclophosphamide in breast cancer. *Journal of Clinical Oncology* **24** 4236–4244. (<https://doi.org/10.1200/JCO.2006.05.6861>)
- Hilfenhaus G, Gohrig A, Pape UF, Neumann T, Jann H, Zdunek D, Hess G, Stassen JM, Wiedenmann B, Detjen K, *et al.* 2013 Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients. *Endocrine-Related Cancer* **20** 305–319. (<https://doi.org/10.1530/ERC-12-0223>)
- Hofland J, Feelders RA, Brabander T, Franssen GJH & de Herder WW 2018 Recent developments in the diagnosis and therapy of well-differentiated neuroendocrine tumours. *Netherlands Journal of Medicine* **76** 100–108.
- Holbourn KP, Acharya KR & Perbal B 2008 The CCN family of proteins: structure-function relationships. *Trends in Biochemical Sciences* **33** 461–473. (<https://doi.org/10.1016/j.tibs.2008.07.006>)
- Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, *et al.* 2018 Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. *Journal of Nuclear Medicine* **59** 66–74. (<https://doi.org/10.2967/jnumed.117.202275>)
- Hu R, Yan Y, Li Q, Lin Y, Jin W, Li H, Lu Y & Pang T 2010 Increased drug efflux along with midline gene high expression in childhood B-lineage acute lymphoblastic leukemia cells. *International Journal of Hematology* **92** 105–110. (<https://doi.org/10.1007/s12185-010-0613-x>)
- Huang D, Ding Y, Zhou M, Rini BI, Pettito D, Qian CN, Kahnoski R, Futreal PA, Furge KA & Teh BT 2010 Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. *Cancer Research* **70** 1063–1071. (<https://doi.org/10.1158/0008-5472.CAN-09-3965>)
- Huang YG, Li YF, Wang LP & Zhang Y 2013 Aberrant expression of trefoil factor 3 is associated with colorectal carcinoma metastasis. *Journal of Cancer Research and Therapeutics* **9** 376–380. (<https://doi.org/10.4103/0973-1482.119308>)
- Hussain F, Wang J, Ahmed R, Guest SK, Lam EW, Stamp G & El-Bahrawy M 2010 The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. *Cytokine* **49** 134–140. (<https://doi.org/10.1016/j.cyto.2009.11.010>)
- Isgro MA, Bottoni P & Scatena R 2015 Neuron-specific enolase as a biomarker: biochemical and clinical aspects. *Advances in Experimental Medicine and Biology* **867** 125–143. (https://doi.org/10.1007/978-94-017-7215-0_9)
- Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovskaya I, *et al.* 2012 Genome sequencing identifies a basis for everolimus sensitivity. *Science* **338** 221. (<https://doi.org/10.1126/science.1226344>)
- Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E & Oberg K 1997 Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. *Annals of Oncology* **8** 685–690. (<https://doi.org/10.1023/A:1008215730767>)
- Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schlick RD, Tang LH, Wolfgang CL, Choti MA, *et al.* 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science* **331** 1199–1203. (<https://doi.org/10.1126/science.1200609>)
- Jin CD, Kim MH, Guo LZ, Li SH & Han J 2015 Falsely high B-type natriuretic peptide concentration in patients without heart failure attributed to AxSYM assay: case series of eight subjects. *ESC Heart Failure* **2** 37–39. (<https://doi.org/10.1002/ehf2.12024>)
- Jones DR 2014 Measuring midline: the utility of midline as a biomarker in cancer and other diseases. *British Journal of Pharmacology* **171** 2925–2939. (<https://doi.org/10.1111/bph.12601>)
- Jorgensen LG, Lober J, Carlsen NL, Momsen G & Hirsch FR 1996 Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay. *Clinica Chimica Acta* **249** 77–91.
- Kaemmerer D, Reimann C, Specht E, Wirtz RM, Sayeg M, Baum RP, Schulz S & Lupp A 2015 Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms. *Oncotarget* **6** 3346–3358. (<https://doi.org/10.18632/oncotarget.3242>)
- Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Graveriaux E, Pieczek A, Iwaguro H, Hayashi SI, Isner JM, *et al.* 2000 Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. *Circulation Research* **86** 1198–1202. (<https://doi.org/10.1161/01.RES.86.12.1198>)
- Kalkner KM, Janson ET, Nilsson S, Carlsson S, Oberg K & Westlin JE 1995 Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. *Cancer Research* **55** 5801s–5804s.
- Kanakakis G, Grimelius L, Spathis A, Tringidou R, Rassidakis GZ, Oberg K, Kaltsas G & Tsolakis AV 2015 Expression of somatostatin Receptors 1–5 and dopamine Receptor 2 in lung carcinoids: implications for a therapeutic role. *Neuroendocrinology* **101** 211–222. (<https://doi.org/10.1159/000381061>)
- Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M & Meyer T 2011 Circulating tumor cells and EpCAM expression in neuroendocrine tumors. *Clinical Cancer Research* **17** 337–345. (<https://doi.org/10.1158/1078-0432.CCR-10-1776>)
- Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME & Meyer T 2013 Circulating tumor cells as prognostic markers in neuroendocrine tumors. *Journal of Clinical Oncology* **31** 365–372. (<https://doi.org/10.1200/JCO.2012.44.2905>)
- Kidd M, Drozdov I & Modlin I 2015 Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. *Endocrine-Related Cancer* **22** 561–575. (<https://doi.org/10.1530/ERC-15-0092>)
- Kim ST, Ha SY, Lee S, Ahn S, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim KM, *et al.* 2016 The impact of PD-L1 expression in patients with metastatic GEP-NETs. *Journal of Cancer* **7** 484–489. (<https://doi.org/10.7150/jca.13711>)
- Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, *et al.* 2017 Alternative lengthening of telomeres in primary pancreatic neuroendocrine neoplasms is associated with aggressive clinical behavior and poor survival. *Clinical Cancer Research* **23** 1598–1606.
- Korner M, Waser B, Schonbrunn A, Perren A & Reubi JC 2012 Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. *American Journal of Surgical Pathology* **36** 242–252. (<https://doi.org/10.1097/PAS.0b013e31823d07f3>)
- Korse CM, Bonfrer JM, Aaronson NK, Hart AA & Taal BG 2009a Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. *Neuroendocrinology* **89** 296–301. (<https://doi.org/10.1159/000162876>)
- Korse CM, Taal BG, de Groot CA, Bakker RH & Bonfrer JM 2009b Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. *Journal of Clinical Oncology* **27** 4293–4299. (<https://doi.org/10.1200/JCO.2008.18.7047>)
- Korse CM, Taal BG, Bonfrer JM, Vincent A, van Velthuisen ML & Baas P 2011 An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival. *Annals of Oncology* **22** 2625–2630. (<https://doi.org/10.1093/annonc/mdr007>)
- Korse CM, Holdenrieder S, Zhi XY, Zhang X, Qiu L, Geistanger A, Lisy MR, Wehnl B, van den Broek D, Escudero JM, *et al.* 2015 Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. *Clinica Chimica Acta* **438** 388–395. (<https://doi.org/10.1016/j.cca.2014.09.015>)

- Kulke MH, Hornick JL, Fraumeni JF Jr, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, *et al.* 2009 O6-Methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. *Clinical Cancer Research* **15** 338–345. (<https://doi.org/10.1158/1078-0432.CCR-08-1476>)
- Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, *et al.* 2010 NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. *Pancreas* **39** 735–752.
- Kulke MH, Shah MH, Benson AB, 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, *et al.* 2015 Neuroendocrine tumors, version 1.2015. *Journal of the National Comprehensive Cancer Network* **13** 78–108.
- Kunikowska J, Lewington V & Krolicki L 2017 Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: the impact of 99mTc-HYNICTOC SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon clinical management. *Clinical Nuclear Medicine* **42** 905–911. (<https://doi.org/10.1097/RLU.0000000000001877>)
- Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW & Krenning EP 2010 Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. *Endocrine-Related Cancer* **17** R53–R73. (<https://doi.org/10.1677/ERC-09-0078>)
- La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F & Capella C 2003 Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. *Human Pathology* **34** 18–27. (<https://doi.org/10.1053/hupa.2003.56>)
- Lambertini C, Barzaghi-Rinaudo P, D'Amato L, Schulz S, Nuciforo P & Schmid HA 2013 Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. *Regulatory Peptides* **187** 35–41. (<https://doi.org/10.1016/j.regpep.2013.10.007>)
- Landry CS, Cavaness K, Celinski S & Preskitt J 2014 Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors. *Gland Surgery* **3** 215–218. (<https://doi.org/10.3978/j.issn.2227-684X.2014.10.01>)
- Li J, Luo G, Fu D, Jin C, Hao S, Yang F, Wang X, Yao L & Ni Q 2011 Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors. *Medical Oncology* **28** 1027–1031. (<https://doi.org/10.1007/s12032-010-9611-3>)
- Li SC, Essaghier A, Martijn C, Lloyd RV, Demoulin JB, Oberg K & Giandomenico V 2013 Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. *Modern Pathology* **26** 685–696. (<https://doi.org/10.1038/modpathol.2012.216>)
- Lin WW & Hsieh SL 2011 Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. *Biochemical Pharmacology* **81** 838–847. (<https://doi.org/10.1016/j.bcp.2011.01.011>)
- Liu L & Gerson SL 2006 Targeted modulation of MGMT: clinical implications. *Clinical Cancer Research* **12** 328–331. (<https://doi.org/10.1158/1078-0432.CCR-05-2543>)
- Liu B, Tang LH, Liu Z, Mei M, Yu R, Dhall D, Qiao XW, Zhang TP, Zhao YP, Liu TH, *et al.* 2014 Alpha-interneixin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness. *Journal of Clinical Endocrinology and Metabolism* **99** E786–E795. (<https://doi.org/10.1210/jc.2013-2874>)
- Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, *et al.* 2013 Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. *Cancer Research* **73** 1733–1741. (<https://doi.org/10.1158/0008-5472.CAN-12-2384>)
- Mafficini A & Scarpa A 2018 Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium. *Journal of Endocrinology* **236** R161–R167. (<https://doi.org/10.1530/JOE-17-0560>)
- Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ & Perren A 2014 Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. *Gastroenterology* **146** e455–e460. (<https://doi.org/10.1053/j.gastro.2013.10.020>)
- Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A & Faggiano A 2018 Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. *Endocrine-Related Cancer* **25** R11–R29. (<https://doi.org/10.1530/ERC-17-0269>)
- Marzese DM, Hirose H & Hoon DS 2013 Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. *Expert Review of Molecular Diagnostics* **13** 827–844. (<https://doi.org/10.1586/14737159.2013.845088>)
- Mateo J, Heymach JV & Zurita AJ 2012 Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. *Molecular Diagnosis and Therapy* **16** 151–161. (<https://doi.org/10.2165/11632590-000000000-00000>)
- McDonald TJ, Jorvall H, Nilsson G, Vagne M, Ghatei M, Bloom SR & Mutt V 1979 Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. *Biochemical and Biophysical Research Communications* **90** 227–233. ([https://doi.org/10.1016/0006-291X\(79\)91614-0](https://doi.org/10.1016/0006-291X(79)91614-0))
- Metz DC & Jensen RT 2008 Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. *Gastroenterology* **135** 1469–1492. (<https://doi.org/10.1053/j.gastro.2008.05.047>)
- Mihaly SR, Ninomiya-Tsuji J & Morioka S 2014 TAK1 control of cell death. *Cell Death and Differentiation* **21** 1667–1676. (<https://doi.org/10.1038/cdd.2014.123>)
- Miller HC, Frampton AE, Malczewska A, Ottaviani S, Stronach EA, Flora R, Kaemmerer D, Schwach G, Pragner R, Faiz O, *et al.* 2016 MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. *Endocrine-Related Cancer* **23** 711–726. (<https://doi.org/10.1530/ERC-16-0044>)
- Mizutani G, Nakanishi Y, Watanabe N, Honma T, Obana Y, Seki T, Ohni S & Nemoto N 2012 Expression of somatostatin receptor (sstr) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-Time RT-PCR method and immunohistochemistry. *Acta Histochemica and Cytochemica* **45** 167–176. (<https://doi.org/10.1267/ahc.12006>)
- Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, *et al.* 2008 Gastroenteropancreatic neuroendocrine tumours. *Lancet Oncology* **9** 61–72. ([https://doi.org/10.1016/S1470-2045\(07\)70410-2](https://doi.org/10.1016/S1470-2045(07)70410-2))
- Modlin IM, Gustafsson BI, Moss SE, Pavel M, Tzolakis AV & Kidd M 2010a Chromogranin A – biological function and clinical utility in neuro endocrine tumor disease. *Annals of Surgical Oncology* **17** 2427–2443. (<https://doi.org/10.1245/s10434-010-1006-3>)
- Modlin IM, Gustafsson BI, Pavel M, Svejda B, Lawrence B & Kidd M 2010b A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. *Neuroendocrinology* **92** 143–157. (<https://doi.org/10.1159/000319784>)
- Modlin IM, Drozdov I & Kidd M 2013 The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. *PLoS One* **8** e63364. (<https://doi.org/10.1371/journal.pone.0063364>)
- Modlin IM, Drozdov I, Bodei L & Kidd M 2014a Blood transcript analysis and metastatic recurrent small bowel carcinoid management. *BMC Cancer* **14** 564. (<https://doi.org/10.1186/1471-2407-14-564>)
- Modlin IM, Oberg K, Taylor A, Drozdov I, Bodei L & Kidd M 2014b Neuroendocrine tumor biomarkers: current status and perspectives. *Neuroendocrinology* **100** 265–277. (<https://doi.org/10.1159/000368363>)

- Modlin IM, Kidd M, Bodei L, Drozdov I & Aslanian H 2015 The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. *American Journal of Gastroenterology* **110** 1223–1232. (<https://doi.org/10.1038/ajg.2015.160>)
- Modlin IM, Bodei L & Kidd M 2016 Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms. *Best Practice and Research in Clinical Endocrinology and Metabolism* **30** 59–77.
- Namwongprom S, Wong FC, Tateishi U, Kim EE & Boonyaprapa S 2008 Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. *Annals of Nuclear Medicine* **22** 237–243. (<https://doi.org/10.1007/s12149-007-0123-y>)
- Nathke I 2006 Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC. *Nature Reviews Cancer* **6** 967–974.
- Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G & Borson-Chazot F 2004 Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. *Clinical Endocrinology* **60** 644–652. (<https://doi.org/10.1111/j.1365-2265.2004.02030.x>)
- Niederle B, Pape U-F, Costa F, Gross D, Kelestimur F, Knigge U, Oberg K, Pavel M, Perren A, Toumpanakis C, *et al.* 2016 ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. *Neuroendocrinology* **103** 125–138. (<https://doi.org/10.1159/000443170>)
- Nikou GC, Marinou K, Thomakos P, Papageorgiou D, Sanzanidis V, Nikolaou P, Kosmidis C, Moulakakis A & Mallas E 2008 Chromogranin A levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. *Pancreatology* **8** 510–519.
- Niu G & Chen X 2010 Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. *Current Drug Targets* **11** 1000–1017.
- Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R & Lamberts SW 1997 Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. *Journal of Clinical Endocrinology and Metabolism* **82** 2622–2628. (<https://doi.org/10.1210/jcem.82.8.4145>)
- Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, Heikamp E, McDevitt MR, Scheinberg DA, Benezra R, *et al.* 2007 Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. *Genes and Development* **21** 1546–1558. (<https://doi.org/10.1101/gad.436307>)
- Nolting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Herrmann KA, Hoffmann JN, Spitzweg C, Goke B & Auernhammer CJ 2012 Chromogranin A as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. *Cancers* **4** 141–155.
- Oberg K, Knigge U, Kwekkeboom D & Perren A & Group EGW 2012 Neuroendocrine gastro-entero-pancreatic tumors ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* **23** (Supplement 7) vii124–vii130.
- Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, *et al.* 2015 Consensus on biomarkers for neuroendocrine tumour disease. *Lancet Oncology* **16** e435–e446.
- Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, *et al.* 2016 A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. *Endocrine Connections* **5** 174–187. (<https://doi.org/10.1530/EC-16-0043>)
- Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, *et al.* 2017 Enets consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. *Neuroendocrinology* **105** 201–211. (<https://doi.org/10.1159/000472254>)
- Obexer P & Ausserlechner MJ 2014 X-linked inhibitor of apoptosis protein – a critical death resistance regulator and therapeutic target for personalized cancer therapy. *Frontiers in Oncology* **4** 197. (<https://doi.org/10.3389/fonc.2014.00197>)
- Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y & Zang X 2015 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. *Trends in Molecular Medicine* **21** 24–33.
- O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape UF, Plockinger U & Mallorca Consensus Conference & European Neuroendocrine Tumor S 2009 ENETS consensus guidelines for the standards of care in neuroendocrine tumors biochemical markers. *Neuroendocrinology* **90** 194–202.
- Ozbudak IH, Shilo K, Tavora F, Rassaei N, Chu WS, Fukuoka J, Jen J, Travis WD & Franks TJ 2009 Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. *Modern Pathology* **22** 633–638. (<https://doi.org/10.1038/modpathol.2009.6>)
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, *et al.* 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* **304** 1497–1500. (<https://doi.org/10.1126/science.1099314>)
- Panarelli N, Tyryshkin K, Wong JJM, Majewski A, Yang X, Scognamiglio T, Kim MK, Bogardus K, Tuschl T, Chen YT, *et al.* 2019 Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. *Endocrine-Related Cancer* **26** 47–57. (<https://doi.org/10.1530/ERC-18-0244>)
- Panzuto F, Severi C, Cannizzaro R, Falconi M, Angeletti S, Pasquali A, Corleto VD, Annibale B, Buonadonna A, Pederzoli P, *et al.* 2004 Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. *Journal of Endocrinological Investigation* **27** 6–11. (<https://doi.org/10.1007/BF03350903>)
- Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B & Plockinger U 2004 Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. *Annals of the New York Academy of Sciences* **1014** 222–233.
- Park C, Ha SY, Kim ST, Kim HC, Heo JS, Park YS, Lauwers G, Lee J & Kim KM 2016 Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. *Oncotarget* **7** 4024–4035. (<https://doi.org/10.18632/oncotarget.6602>)
- Parr C, Watkins G, Boulton M, Cai J & Jiang WG 2005 Placenta growth factor is over-expressed and has prognostic value in human breast cancer. *European Journal of Cancer* **41** 2819–2827.
- Pavel ME, Hassler G, Baum U, Hahn EG, Lohmann T & Schuppan D 2005 Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. *Clinical Endocrinology* **62** 434–443.
- Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebowitz D, Jehl V, Wolin EM, *et al.* 2011 Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet* **378** 2005–2012. ([https://doi.org/10.1016/S0140-6736\(11\)61742-X](https://doi.org/10.1016/S0140-6736(11)61742-X))
- Pavel ME, Baudin E, Oberg KE, Hainsworth JD, Voi M, Rouyre N, Peeters M, Gross DJ & Yao JC 2017 Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. *Annals of Oncology* **28** 1569–1575.
- Powles T, Eder JP, Fine GD, Braithe FS, Lorient Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, *et al.* 2014 MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature* **515** 558–562.

- Raj N, Klimstra DS, Horvat N, Zhang L, Chou JF, Capanu M, Basturk O, Do RKG, Allen PJ & Reidy-Lagunes D 2017 O6-methylguanine DNA methyltransferase status does not predict response or resistance to alkylating agents in well-differentiated pancreatic neuroendocrine tumors. *Pancreas* **46** 758–763. (<https://doi.org/10.1097/MPA.0000000000000842>)
- Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, *et al.* 2012 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). *Gut* **61** 6–32. (<https://doi.org/10.1136/gutjnl-2011-300831>)
- Reddy KB 2015 MicroRNA (miRNA) in cancer. *Cancer Cell International* **15** 38. (<https://doi.org/10.1186/s12935-015-0185-1>)
- Resel Folkersma L, San Jose Manso L, Galante Romo I, Moreno Sierra J & Olivier Gomez C 2012 Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. *Urology* **80** 1328–1332.
- Reubi JC, Waser B, Cescato R, Gloor B, Stettler C & Christ E 2010 Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. *Journal of Clinical Endocrinology and Metabolism* **95** 2343–2350. (<https://doi.org/10.1210/jc.2009-2487>)
- Rickman OB, Vohra PK, Sanyal B, Vrana JA, Aubry MC, Wigle DA & Thomas CF, Jr 2009 Analysis of ErbB receptors in pulmonary carcinoid tumors. *Clinical Cancer Research* **15** 3315–3324. (<https://doi.org/10.1158/1078-0432.CCR-08-2549>)
- Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G & Papotti M 2010 Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. *Annals of Oncology* **21** 548–555. (<https://doi.org/10.1093/annonc/mdp334>)
- Rizzo FM & Meyer T 2018 Liquid biopsies for neuroendocrine tumors: circulating tumor cells, DNA, and microRNAs. *Endocrinology and Metabolism Clinics of North America* **47** 471–483.
- Roberts JA, Gonzalez RS, Das S, Berlin J & Shi C 2017 Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. *Human Pathology* **70** 49–54. (<https://doi.org/10.1016/j.humpath.2017.10.003>)
- Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, *et al.* 2006 MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. *Journal of Clinical Oncology* **24** 4677–4684. (<https://doi.org/10.1200/JCO.2005.05.5194>)
- Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, *et al.* 2014 Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. *Annals of Oncology* **25** 1959–1965. (<https://doi.org/10.1093/annonc/mdu288>)
- Ruebel K, Leontovich AA, Stilling GA, Zhang S, Righi A, Jin L & Lloyd RV 2010 MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. *Modern Pathology* **23** 367–375.
- Rusch VW, Klimstra DS & Venkatraman ES 1996 Molecular markers help characterize neuroendocrine lung tumors. *Annals of Thoracic Surgery* **62** 798–809; discussion 809–710.
- Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D & Bertucci F 2015 Prognostic and predictive value of PDL1 expression in breast cancer. *Oncotarget* **6** 5449–5464. (<https://doi.org/10.18632/oncotarget.3216>)
- Sampedro-Nunez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibanez-Costa A, Martin-Perez E, Culler MD, *et al.* 2016 Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. *Oncotarget* **7** 6593–6608.
- Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, *et al.* 2017 Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature* **543** 65–71. (<https://doi.org/10.1038/nature21063>)
- Schimmack S, Lawrence B, Svejda B, Alaimo D, Schmitz-Winnenthal H, Fischer L, Buchler MW, Kidd M & Modlin I 2012 The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms. *Cancer* **118** 2763–2775. (<https://doi.org/10.1002/cncr.26592>)
- Schmitt AM, Pavel M, Rudolph T, Dawson H, Blank A, Komminoth P, Vassella E & Perren A 2014 Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms. *Neuroendocrinology* **100** 35–44. (<https://doi.org/10.1159/000365514>)
- Schuller M, Jenne D & Voltz R 2005 The human PNMA family: novel neuronal proteins implicated in paraneoplastic neurological disease. *Journal of Neuroimmunology* **169** 172–176. (<https://doi.org/10.1016/j.jneuroim.2005.08.019>)
- Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, Zander T, Wolf J & Buettner R 2015 PD-L1 expression in small cell neuroendocrine carcinomas. *European Journal of Cancer* **51** 421–426. (<https://doi.org/10.1016/j.ejca.2014.12.006>)
- Schurmann G, Raeth U, Wiedenmann B, Buhr H & Herfarth C 1992 Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. *World Journal of Surgery* **16** 697–701; discussion 701–692.
- Schwartz TW 1983 Pancreatic polypeptide: a hormone under vagal control. *Gastroenterology* **85** 1411–1425.
- Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, *et al.* 2012 Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* **482** 226–231. (<https://doi.org/10.1038/nature10833>)
- Seregini E, Ferrari L, Bajetta E, Martinetti A & Bombardieri E 2001 Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. *Annals of Oncology* **12** (Supplement 2) S69–S72.
- Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP & Caplin ME 2006 Epidermal growth factor receptor expression and activation in neuroendocrine tumours. *Journal of Neuroendocrinology* **18** 355–360. (<https://doi.org/10.1111/j.1365-2826.2006.01425.x>)
- Sikora K, Bedin C, Vicentini C, Malpeli G, D’Angelo E, Sperandio N, Lawlor RT, Bassi C, Tortora G, Nitti D, *et al.* 2015 Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. *International Journal of Biological Markers* **30** e136–e141. (<https://doi.org/10.5301/ijbm.5000088>)
- Srivastava A, Alexander J, Lomakin I & Dayal Y 2001 Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors. *Human Pathology* **32** 1184–1189. (<https://doi.org/10.1053/hupa.2001.28959>)
- Stevenson M, Lines KE & Thakker RV 2018 Molecular genetic studies of pancreatic neuroendocrine tumors: new therapeutic approaches. *Endocrinology and Metabolism Clinics of North America* **47** 525–548. (<https://doi.org/10.1016/j.ecl.2018.04.007>)
- Stivanello M, Berruti A, Torta M, Termine A, Tampellini M, Gorzegno G, Angeli A & Dogliotti L 2001 Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. *Annals of Oncology* **12** (Supplement 2) S73–S77.
- Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, *et al.* 2017 Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. *New England Journal of Medicine* **376** 125–135.

- Tecimer T, Dlott J, Chuntharapai A, Martin AW & Peiper SC 2000 Expression of the chemokine receptor CXCR2 in normal and neoplastic neuroendocrine cells. *Archives of Pathology and Laboratory Medicine* **124** 520–525. ([https://doi.org/10.1043/0003-9985\(2000\)124<0520:EOTCRC>2.0.CO;2](https://doi.org/10.1043/0003-9985(2000)124<0520:EOTCRC>2.0.CO;2))
- Terris B, Scazecz JY, Rubbia L, Bregeaud L, Pepper MS, Ruzsniowski P, Belghiti J, Flejou J & Degott C 1998 Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. *Histopathology* **32** 133–138.
- Thorns C, Schurmann C, Gebauer N, Wallaschofski H, Kumpers C, Bernard V, Feller AC, Keck T, Habermann JK, Begum N, *et al.* 2014 Global microRNA profiling of pancreatic neuroendocrine neoplasias. *Anticancer Research* **34** 2249–2254.
- Tomassetti P, Migliori M, Simoni P, Casadei R, De lasio R, Corinaldesi R & Gullo L 2001 Diagnostic value of plasma chromogranin A in neuroendocrine tumours. *European Journal of Gastroenterology and Hepatology* **13** 55–58.
- Tsuruoka K, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Asakura K, Nakagawa K, Sakurai H, *et al.* 2017 PD-L1 expression in neuroendocrine tumors of the lung. *Lung Cancer* **108** 115–120.
- Turner GB, Johnston BT, McCance DR, McGinty A, Watson RG, Patterson CC & Ardill JE 2006 Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. *Gut* **55** 1586–1591. (<https://doi.org/10.1136/gut.2006.092320>)
- van Adrichem RC, Kamp K, van Deurzen CH, Biermann K, Feelders RA, Franssen GJ, Kwekkeboom DJ, Hofland LJ & de Herder WW 2016a Is there an additional value of using somatostatin receptor subtype 2a immunohistochemistry compared to somatostatin receptor scintigraphy uptake in predicting gastroenteropancreatic neuroendocrine tumor response? *Neuroendocrinology* **103** 560–566. (<https://doi.org/10.1159/000441604>)
- van Adrichem RC, Kamp K, Vandamme T, Peeters M, Feelders RA & de Herder WW 2016b Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. *Annals of Oncology* **27** 746–747. (<https://doi.org/10.1093/annonc/mdv626>)
- van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK & Kwekkeboom DJ 2015 GEPNETs update: radionuclide therapy in neuroendocrine tumors. *European Journal of Endocrinology* **172** R1–R8. (<https://doi.org/10.1530/EJE-14-0488>)
- van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, *et al.* 2002 Gene expression profiling predicts clinical outcome of breast cancer. *Nature* **415** 530–536. (<https://doi.org/10.1038/415530a>)
- VandenBussche CJ, Allison DB, Graham MK, Charu V, Lennon AM, Wolfgang CL, Hruban RH & Heaphy CM 2017 Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. *Cancer Cytopathology* **125** 544–551. (<https://doi.org/10.1002/cncy.21857>)
- Veenendaal LM, Borel Rinkes IH, Lips CJ & van Hillegersberg R 2006 Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. *World Journal of Surgical Oncology* **4** 35. (<https://doi.org/10.1186/1477-7819-4-35>)
- Vestergaard EM, Nexø E, Tørring N, Borre M, Orntoft TF & Sørensen KD 2010 Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. *International Journal of Cancer* **127** 1857–1865.
- Vicentini C, Fassan M, D'Angelo E, Corbo V, Silvestris N, Nuovo GJ & Scarpa A 2014 Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract. *Molecules* **19** 2458–2468. (<https://doi.org/10.3390/molecules19022458>)
- Walter T, Chardon L, Chopin-Jaly X, Raverot V, Caffin AG, Chayvialle JA, Scazecz JY & Lombard-Bohas C 2012 Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? *European Journal of Cancer* **48** 1766–1773. (<https://doi.org/10.1016/j.ejca.2011.11.005>)
- Walter T, van Brakel B, Vercherat C, Hervieu V, Forestier J, Chayvialle JA, Molin Y, Lombard-Bohas C, Joly MO & Scazecz JY 2015 O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. *British Journal of Cancer* **112** 523–531. (<https://doi.org/10.1038/bjc.2014.660>)
- Wang YH, Yang QC, Lin Y, Xue L, Chen MH & Chen J 2014 Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. *Medicine* **93** e247. (<https://doi.org/10.1097/MD.0000000000000247>)
- Wei SC, Liang JT, Tsao PN, Hsieh FJ, Yu SC & Wong JM 2009 Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer. *Diseases of the Colon and Rectum* **52** 1630–1636. (<https://doi.org/10.1007/DCR.0b013e3181afbda>)
- Wong KK, Waterfield RT, Marzola MC, Scarsbrook AF, Chowdhury FU, Gross MD & Rubello D 2012 Contemporary nuclear medicine imaging of neuroendocrine tumours. *Clinical Radiology* **67** 1035–1050. (<https://doi.org/10.1016/j.crad.2012.03.019>)
- Wu X, Zhi X, Ji M, Wang Q, Li Y, Xie J & Zhao S 2015 Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy. *American Journal of Cancer Research* **5** 629–638.
- Xavier S, Rosa B & Cotter J 2016 Small bowel neuroendocrine tumors: from pathophysiology to clinical approach. *World Journal of Gastrointestinal Pathophysiology* **7** 117–124. (<https://doi.org/10.4291/wjgp.v7.i1.117>)
- Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, *et al.* 2008 One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *Journal of Clinical Oncology* **26** 3063–3072. (<https://doi.org/10.1200/JCO.2007.15.4377>)
- Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruzsniowski P, Hoosen S, St Peter J, Haas T, Lebwohl D, *et al.* 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. *Journal of Clinical Oncology* **28** 69–76. (<https://doi.org/10.1200/JCO.2009.24.2669>)
- Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A & Öberg KE 2011 Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. *Journal of Clinical Endocrinology and Metabolism* **96** 3741–3749. (<https://doi.org/10.1210/jc.2011-0666>)
- Yao JC, Shah M, Panneerselvam A, Stergiopoulos S, Chen D, Ito T & Pavel M 2012 The VEGF pathway in patients with pancreatic neuroendocrine tumors: efficacy of everolimus by baseline marker level, and prognostic and predictive effect analysis from radiant-3. ESMO Congress 2012 abstract 11540.
- Yap TA, Yan L, Patnaik A, Fearon I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, *et al.* 2011 First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. *Journal of Clinical Oncology* **29** 4688–4695.
- Zandee WT, Kamp K, van Adrichem RC, Feelders RA & de Herder WW 2016 Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. *European Journal of Endocrinology* **175** 361–366. (<https://doi.org/10.1530/EJE-16-0392>)
- Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L, degli Uberti EC, *et al.* 2007 Chromogranin A as a marker of neuroendocrine neoplasia: an Italian multicenter study. *Endocrine-Related Cancer* **14** 473–482. (<https://doi.org/10.1677/ERC-07-0001>)
- Zatelli MC, Grossrubatscher EM, Guadagno E, Sciammarella C, Faggiano A & Colao A 2017 Circulating tumor cells and miRNAs as

- prognostic markers in neuroendocrine neoplasms. *Endocrine-Related Cancer* **24** R223–R237. (<https://doi.org/10.1530/ERC-17-0091>)
- Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K & Yao JC 2007 Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. *Cancer* **109** 1478–1486. (<https://doi.org/10.1002/cncr.22554>)
- Zimmermann N, Knief J, Kacprowski T, Lazar-Karsten P, Keck T, Billmann F, Schmid S, Luley K, Lehnert H, Brabant G, *et al.* 2018 MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases. *Oncotarget* **9** 28379–28390. (<https://doi.org/10.18632/oncotarget.25357>)
- Zuetaenhorst JM & Taal BG 2005 Metastatic carcinoid tumors: a clinical review. *Oncologist* **10** 123–131. (<https://doi.org/10.1634/theoncologist.10-2-123>)
- Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, *et al.* 2015 Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. *British Journal of Cancer* **112** 1199–1205. (<https://doi.org/10.1038/bjc.2015.73>)

Received in final form 12 December 2018

Accepted 3 January 2019

Accepted Preprint published online 7 January 2019